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ABSTRACT 
 
Denise Elena Allard; Schwann cells promote spontaneous autoimmune peripheral 
polyneuropathy 
(Under the direction of Maureen A. Su) 
 
 Chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-Barré 
syndrome (GBS) are autoimmune demyelinating diseases of the peripheral nervous 
system (PNS). During CIDP and GBS, the immune system attacks Schwann cells that 
compose the myelin sheath leading to impaired sensorimotor nerve function; however, 
Schwann cells are not merely passive bystanders in this autoimmune attack. We show 
here that Schwann cells actively promote disease pathogenesis in murine models of 
CIDP and GBS through upregulation of the extracellular matrix (ECM) protein periostin 
(Postn) and integrin (Itg)-α2 (CD49b). Firstly, increased Postn secretion by Schwann 
cells directly promoted macrophage chemotaxis into the PNS via interaction with ItgαV 
and ItgαM (CD11b). We also showed that although PNS-infiltrating macrophages 
expressed both pro- and anti-inflammatory markers, macrophages in the PNS are 
pathogenic effectors since their depletion resulted in delayed disease onset and 
reduced disease incidence. Secondly, we showed increased CD49b expression on 
Schwann cells rather than NK cells or NK T cells during neuropathy. CD49b associated 
with the complement protein C1q suggesting a possible immunological role for CD49b. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Autoimmune demyelinating diseases of the peripheral nervous system 
 
1.1.1 Chronic inflammatory demyelinating polyneuropathy  
 
 Chronic inflammatory demyelinating polyneuropathy (CIDP) is a demyelinating 
autoimmune disease of the peripheral nervous system that impacts 1/10,000 people (1). 
In patients with CIDP, sensorimotor impairment develops over a period of at least 8 
weeks and can be relapsing-remitting, gradually progressive, or stepwise progressive 
(2). Symptoms include weakness, abnormal gait, numbness, paresthesia, and reduced 
or absent tendon reflexes. Typical CIDP involves proximal and distal, symmetric 
dysfunction of both sensory and motor neurons; however, CIDP has several phenotypic 
variants which are classified based on the relative involvement of sensory and 
motorneurons and the pattern of peripheral nerve and nerve root involvement (2). A 
diagnosis of CIDP requires evidence of demyelination upon electrophysiologic 
examination, which may include prolonged distal latency, reduced conduction velocity, 
temporal dispersion, prolonged F-wave latency, or conduction block (2). Current first-
line therapies for CIDP include intravenous immunoglobulin (IVIg), plasma exchange, 
and corticosteroids (3). The majority of patients will respond to one of these first-line 
therapies; however, many patients require long-term treatment to maintain the 
therapeutic effect, and despite treatment, a majority of patients suffer permanent nerve 
damage (4).  
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1.1.2 Guillain-Barré Syndrome  
 
 Guillain-Barré Syndrome (GBS) shares many similarities with CIDP; however, 
peak disease severity occurs in less than 4 weeks. Approximately 70% of GBS cases 
occur shortly after an infection. Several infections have been associated with GBS 
including Cytomegalovirus, Epstein Barr virus, influenza A, and Campylobacter jejuni 
(5). In addition to severe weakness and sensory impairment, patients with GBS often 
have involvement of the autonomic nervous system, which may result in urinary 
retention, constipation, hypertension, tachycardia, bradycardia, or respiratory failure (6). 
Treatment for GBS involves general medical care, in conjunction with either IvIg or 
plasma exchange. As many as 30% of GBS patients require intubation and ventilation. 
Unlike CIDP, corticosteroids are not effective treatment options for GBS. The majority of 
GBS patients recover with mild to no residual symptoms; however, mortality due to 
autonomic involvement occurs in 3-7% of patients (5). 
1.2 Targets of autoimmunity in CIDP and GBS: Schwann cells 
 
 Schwann cells, the myelinating cells of the PNS, are required to insulate axons 
and promote rapid conduction of action potentials (saltatory conduction). Schwann cells 
are derived from the neural crest. During development, Schwann cell precursors are 
involved in a process called radial sorting in which Schwann cells first surround and 
then separate axons (7). Schwann cells that associate with a single axon elaborate a 
myelin sheath under the control of the transcription factor Krox20 (8). Major myelin 
proteins of the PNS include myelin protein P0, P2, PMP22. Numerous Schwann cells 
line up along the length of an axon leaving small gaps called nodes of Ranvier between 
them (9). Voltage-gated Na+ (NaV) channels are clustered at the node of Ranvier and 
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are stabilized by neurofascin (NF) 186 and gliomedin (10). At the paranode, contactin-1, 
caspr1, and NF155 interact to form septate junctions that segregate NaV channels at 
the node of Ranvier from voltage-gated K+ (Kv) channels (11, 12), which are localized to 
the juxtaparanode. The complex structure of the nodes of Ranvier act in conjunction 
with the insulating function of the myelin sheath to promote saltatory conduction.  
Following nerve injury, the transcription factor c-Jun is rapidly upregulated by 
Schwann cells (13). c-Jun suppresses the function of Krox20 which is required for 
myelin maintenance, thereby initiating dedifferentiation of Schwann cells to an immature 
state (14). During dedifferentiation, Schwann cells not only reaquire an immature 
phenotype but also upregulate extracellular matrix proteins, autophagy machinery, and 
pro-inflammatory signals (15, 16). Dedifferentiated Schwann cells serve several 
functions in the injured nerve including myelin phagocytosis (17), axon protection (18), 
immune cell recruitment (15), and eventually remyelination. Thus, understanding the 
functions of Schwann cells is critical to understanding the pathogenesis of CIDP and its 
murine model, spontaneous autoimmune peripheral polyneuropathy (SAPP). 
1.3 Tolerance: avoiding autoimmunity 
 
 As part of the adaptive immune system, T cells are tasked with identifying rapidly 
evolving pathogens. In order to recognize the greatest number of possible protein 
antigens including antigens that do not yet exist, T cell receptors (TCR) are generated 
randomly through VDJ recombination. The random nature of TCR generation results in 
T cells that recognize not only foreign antigens but also normal host antigens. In order 
to protect the body from self-reactive T cells the immune system has developed a 
number of mechanisms to delete or inactivate self-reactive T cells that are collectively 
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known as tolerance. There are two main classes of tolerance known as central 
tolerance, which occurs in the thymus during T cell development, and peripheral 
tolerance, which occurs once T cells have exited the thymus (19). 
 The most prominent mechanism of central tolerance is known as negative 
selection. During negative selection, medullary thymic epithelial cells (mTECs) express 
tissue-specific antigens (TSA), which are regulated by the transcription factor 
autoimmune regulator (Aire). TSAs are then presented to T cells by mTECs or thymic 
dendritic cells (DC), which acquire TSAs from mTECs. T cells bearing a TCR that reacts 
with high affinity to peptide-MHC complexes undergo apoptosis, thus preventing 
autoimmunity (20). Alternatively, highly self-reactive T cells may be converted in the 
thymus into natural regulatory T cells (Treg), which suppress the immune response 
through various mechanisms including the secretion of anti-inflammatory cytokines, 
cytotoxic T lymphocyte associated protein 4 (CTLA-4), and modulation of APCs (21).  
 Peripheral tolerance mechanisms include anergy, and activation-induced cell 
death (AICD). In anergy, TCR signaling and IL-2 expression are actively repressed and 
the T cell becomes functionally inactive due to lack of adequate costimulation, which is 
required for T cell activation. In AICD, repetitive TCR signaling induces the 
coexpression of tumor necrosis factor receptor superfamily, member 6/CD95 (Fas) and 
Fas ligand (FasL) on T cells, and leads to Fas-mediated apoptosis (22). Disruption of 
any of these central or peripheral tolerance mechanisms can lead to autoimmunity 
including autoimmunity of the PNS.    
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1.4 Pathogenesis of CIDP and GBS: immune involvement 
 
1.4.1 T cells in peripheral neuropathy 
 
 T cells have been observed in sural nerve biopsies from CIDP (2) and GBS (23) 
patients and are thought to be major mediators of demyelination in these diseases. 
Disruption of central and peripheral T cell tolerance mechanisms results in the 
spontaneous development of peripheral neuropathy indicating a critical role for T cells in 
the pathogenesis of inflammatory neuropathy. Specifically, mutations in Aire (24, 25) or 
ICAM (26) disrupt negative selection and result in an altered T cell repertoire and an 
increased frequency of P0-specific autoreactive T cells. Additionally, disruption of B7-2 
preferentially impairs activation of T regulatory cells, alters the relative abundance of 
Treg to T effectors, and results in SAPP (27-29). In SAPP models, CD4 T cells are 
sufficient to transfer disease, and are largely interferon (IFN)-γ-producing Th1 T cells 
(24, 30). Furthermore, IFN-γ is required for SAPP pathogenesis (27). 
1.4.2 Macrophages in peripheral neuropathy 
 
Macrophages have been observed in nerve biopsies from CIDP patients (2). 
Similarly, macrophages infiltrate the sciatic nerve during SAPP (24) and experimental 
allergic neuritis (EAN) (31, 32), an animal model of GBS. Macrophages have been 
shown to play diverse roles in PNS pathogenesis and repair. For instance, 
macrophages may promote disease through myelin phagocytosis, antigen presentation 
to T cells (31), and the secretion of pro-inflammatory factors including reactive oxygen 
species (33) and the cytokines interleukin (IL) 12 (34), tumor necrosis factor-α (TNFα) 
(35), and IL-6 (34). Furthermore, macrophage depletion reduces EAN severity (36, 37) 
indicating a pathogenic role for macrophages in inflammatory neuropathies. On the 
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other hand, macrophages also play an active role in recovery from peripheral nerve 
damage. During recovery, macrophages secrete the anti-inflammatory cytokines IL-10 
(38) and TGF-β (39) as well as growth and differentiation factors (31) that promote axon 
regeneration and remyelination.  While macrophages are known to contribute to PNS 
pathogenesis as well as recovery, their function in the setting of chronic inflammation as 
observed in CIDP and SAPP is unclear.  
1.4.3 B cells 
 
The efficacy of plasma exchange therapy in the treatment of CIDP and GBS 
implicates that humoral factors such as antibodies may mediate disease pathogenesis. 
In fact, autoreactive antibodies specific to compact myelin proteins including myelin 
protein P0, P2, and PMP22 or nodal proteins such as gliomedin, neurofascin, contactin-
1, and caspr1 have been identified in both human patients (2) and murine models (24, 
40-44). However, the significance of autoreactive antibodies in CIDP is controversial. 
Human serum from a subset of CIDP patients binds sections of healthy nerve tissue 
indicating the presence of autoreactive antibodies (45, 46). P0-, gliomedin-, and 
contactin-specific autoantibodies can induce conduction block; however, similar 
experiments using P2-, Caspr-, and NF186-specific antibodies failed to transfer disease 
in vivo. (44, 47-49). The inability of certain PNS-reactive antibodies to transfer disease 
raises the question of whether these antibodies are pathogenic or merely 
epiphenomena of disease. B cell depletion experiments in EAN (50, 51) and SAPP (40) 
have been similarly controversial. Experiments in EAN in mice with a genetic B cell 
deficiency have shown conflicting results with one group reporting protection from 
disease (51) and another reporting no change in disease outcome (50). Additionally, 
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clinical trials using the B cell depleting antibody Rituximab in CIDP patients were 
ineffective at improving symptoms (3).  
1.4.4 Complement factor C1q 
 
C1q is the initiating component of the classical complement pathway. C1q is 
composed of three genes: C1q A, B, and C that assemble into a triple helix. Six triple 
helical strands form the intact C1q molecule, which has two functionally and structurally 
distinct domains: the globular domain, which recognizes pathogen and damage 
associated molecular patterns, and the collagen-like domain (52, 53), which can interact 
with CD49b (54, 55). In addition to activating the classical complement pathway, C1q 
functions to opsonize apoptotic and necrotic debris, regulate DC maturation, and induce 
cytokine secretion, as well as other emerging functions (52, 53). For example, 
interaction between CD49b and C1q is required for interleukin (IL)-6 secretion by mast 
cells during infection (54). The pro- and anti- inflammatory functions of C1q have 
implicated C1q as a major player in autoimmune disease. In fact, C1q is upregulated in 
nerve tissue from CIDP patients (56) and increased activation of the complement 
pathway is associated with disease severity in CIDP (57) and GBS (58, 59).   
1.5 The extracellular matrix and its receptors 
 
1.5.1 Laminins 
 
 Extracellular matrix (ECM) proteins, such as laminins, collagens, and 
proteoglycans, are a diverse group of proteins that not only provide structure to tissues, 
but also promote cell proliferation, migration, and signaling. Laminins are heterotrimetric 
ECM proteins. Laminin 2 (α2β1γ1, previously known as merosin), laminin 8 (α4β1γ1), and 
laminin 10 (α5β1γ1) are major components of the Schwann cell basal lamina and are 
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critical for Schwann cell development and myelination (60, 61). Mutations in laminin α2, 
α4, or γ1 result in hereditary peripheral neuropathy caused by defects in radial sorting 
and reduced Schwann cell proliferation during development in both human (62) and 
mouse (63-65). Following nerve injury, ECM protein expression changes: laminin α3 is 
upregulated during the degenerative phase of Wallerian degeneration (WD) and laminin 
α2 is upregulated during the recovery phase, while collagen expression slowly and 
continually increases following injury (66, 67). The importance of ECM proteins during 
myelination and following nerve injury suggest an important role for the ECM in 
demyelinating disorders such as CIDP and GBS; however, little is known about ECM 
proteins during PNS autoimmunity.   
1.5.2 ECM protein receptors: Integrins 
 
 Integrins are a class of adhesion receptors composed of heterodimers of one α 
and one β subunit. Integrins bind extracellular matrix proteins to promote cell adhesion 
and migration. In inflammation, integrins are best known for their role in promoting 
immune cell attachment to and extravasation from the vasculature; however, integrins 
also contribute to inflammation within the interstitium (68, 69).  For example, the 
collagen-binding integrins α1β1 and α2β1, which do not participate in immune cell 
extravasation, promote antigen-dependent joint inflammation (68, 70). 
 Schwann cells express numerous integrins including α1β1, α2β1, α6β1, α7β1, 
αVβ3, and αVβ8 (71-73). In the PNS, integrins are important mediators of Schwann cell 
development and regulate Schwann cell polarization as well as radial sorting (74, 75). 
The laminin-binding integrins α6β1 and α7β1 are critical for radial sorting during 
development (75). Additionally, integrin expression patterns on myelinating cells are 
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altered in both CNS and PNS autoimmunity. For instance, ItgαV and β4 are upregulated 
on astrocytes and Itgα2 (CD49b) is upregulated on oligodendrocytes during 
experimental autoimmune encephalomyelitis (EAE) (76). Similarly, Itgα2 expression 
decreases during the acute phase of EAN, a model of GBS, and rebounds during the 
recovery phase (71). Despite clear evidence of integrin regulation on myelinating cells in 
autoimmunity, the functional significance of integrins during demyelinating neuropathy is 
poorly understood. 
1.5.3 Periostin 
 
 Periostin (Postn) is an ECM protein of the fasciclin family and is composed of an 
amino-terminal EMI domain, four fasciclin (FAS) domains, and a carboxyl-terminal 
hydrophilic domain (77). Postn binds other ECM proteins such as collagen and tenascin 
as well as integrins through its EMI and FAS domains respectively. Postn is upregulated 
in various diseases including cancer (78), myocardial infarction (79), asthma (80), skin 
inflammation (81), glomerulonephritis (82), and colitis (83). TGF-β (77), IL-4 and IL-13 
(81), TNF-α and IL-17 (84), or neuregulin/ErbB3 (85) can induce Postn through the 
transcription factors c-Fos and twist (86). Postn signals through integrin (Itg)-αVβ3 (81, 
87), ItgαVβ5 (87), and ItgαM (88)  and results in the phosphorylation of focal adhesion 
kinase (FAK) (89) and AKT(89) and the activation of NF-κB (81, 83). Postn has been 
shown to promote immune cell recruitment to sites of inflammation via both direct (90, 
91) and indirect mechanisms (92). In transwell migration assays, macrophages migrate 
in response to Postn (90, 91). Additionally, Postn regulates various cytokines and 
chemokines including TNF-α (81, 90), IL-1α (81), GM-CSF (81), chemokine ligand 
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CCL17 (81, 91), RANTES (CCL5) (82, 93), CCL2 (92), CCL4 (92), CCL7 (92), and 
CXCL2 (92).     
Postn is expressed by several glial cells including astrocytes (89) and pericytes 
(90) in the central nervous system (CNS), and Schwann cells (85, 94) and endoneurial 
fibroblasts (94) in the PNS. In CNS, Postn expression is detectable as early as 7 days 
post injury and promotes recruitment of macrophages to the site of injury (90). In the 
PNS, Postn is expressed during development (85, 94). In vitro, Postn induces Schwann 
cell migration; however, the development of the nervous system develops normally in 
Postn deficient animals (85). The normal development of the PNS in Postn deficient 
mice suggests that other proteins may compensate for Postn during development; 
however, a role for Postn in PNS autoimmunity has not been investigated.  
1.6 Schwann cells as mediators of autoimmunity 
 
 While progress has been made in decoding the pathogenesis of CIDP and GBS 
pathogenesis with respect to the T cells, macrophages, and B cells, the role of Schwann 
cells has not been investigated. Given Schwann cells’ known function as mediators of 
inflammation following nerve injury, it is likely that Schwann cells also participate in the 
pathogenesis of autoimmune neuropathies; however, little is known about whether and 
how Schwann cells promote inflammation in autoimmunity. This dissertation explores 
two potential roles for Schwann cells, not as targets of autoimmunity, but as pathogenic 
mediators of it. 
 In chapter 2, we show that the expression of Itgα2 (CD49b, recognized by the 
DX5 antibody) is increased during neuropathy on nerve-resident Schwann cells and not 
NK or NKT cells. Furthermore, CD49b colocalizes with complement factor C1q. CD49b 
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is a C1q receptor, we speculate that CD49b expression on Schwann cells promotes 
SAPP via interaction with C1q. 
 The prominent roles of ECM proteins in Schwann cell development and 
inflammatory disease lead us to hypothesize that ECM proteins and Postn in particular 
may regulate SAPP pathogenesis. In chapter 3, we show that the ECM protein Postn is 
upregulated by Schwann cells during SAPP. Furthermore, Postn promotes disease 
because Postn deficiency delays the onset and reduces the severity of peripheral 
neuropathy in an adoptive transfer model. The frequency and number of both T cells 
and macrophages are reduced in Postn deficient compared to Postn sufficient 
neuropathic animals. Postn induces the chemotaxis of macrophages but not T cells via 
interaction with ItgαV and ItgαM (CD11b) in a transwell system. Additionally we show 
that the macrophages recruited to the PNS by Postn are pathogenic since clodronate 
depletion of macrophages protects mice from SAPP.  
In chapter 4, we investigate the role of B cells in SAPP. We show that despite an 
increase in marginal zone B cells, which are associated with autoimmunity, B cells are 
dispensible for the development of SAPP.       
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CHAPTER 2: DX5/CD49b IDENTIFIES AN EXPANDED POPULATION OF 
SCHWANN CELLS ASSOCIATED WITH C1q IN AUTOIMMUNE PERIPHERAL 
NEUROPATHY1 
 
2.1 Introduction 
 
Chronic inflammatory demyelinating polyneuropathy (CIDP) affects 
approximately 1/10,000 (1) people. CIDP is characterized by progressive or relapsing 
and remitting demyelination of the peripheral nervous system (PNS), affecting 
myelinated sensory or motor axons, and can lead to disabling sensory loss and 
weakness. Current first-line therapies include plasma exchange, intravenous 
immunoglobulin, corticosteroids and/or steroid sparing immunosuppresants. Although 
80% of patients respond to one of these first-line treatments, up to 70% of patients 
sustain permanent nerve damage necessitating the development of further treatment 
options (4). CIDP is mediated by both cellular and humoral immune responses that are 
still poorly understood.  
Spontaneous autoimmune peripheral polyneuropathy (SAPP) resembles CIDP, 
and provides a mouse model for investigating the pathways that cause autoimmune 
demyelinating neuropathy. Thymic tolerance, mediated by Aire and ICAM, plays a 
critical role because SAPP develops in non-obese diabetic (NOD) mice with a dominant 
partial loss-of-function mutation in Aire (NOD.AireGW/+ mice) (24, 25) and NOD.ICAM-/- 
                                                          
1 This manuscript will be submitted to the journal Glia. 
Authors: Denise E. Allard, Xiaopei L. Zeng, Yang Wang, Colin-Jamal Smith, Bridget Conley, Caelleigh 
Kimpston, Rebecca Notini, James Howard, Steven Scherer, and Maureen A Su 
Student contribution: I performed the experiments and analyzed the data in figure 2.1A-F, 2.3B, 2.4A-D, 
2.5A-B, and 2.6. I supervised undergraduates who performed experiments in figure 2.1G and 2.5D. I 
wrote the majority of the manuscript and made all of the figures.  
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mice (26). Additionally, SAPP has also been reported in NOD mice deficient in B7-2 
(29). B7-2 deficiency impairs the antigen presenting capacity of CD11b+ dendritic cells 
(DC) (95) and alters the balance of regulatory to effector populations. Impaired-DC 
function in B7-2 deficient mice preferentially impacts regulatory populations leading to a 
reduced frequency of regulatory T cells (Treg) (27, 28) and regulatory B cells (Breg) (28). 
The effector populations in SAPP include both T cells and B cells. T cells that infiltrate 
the sciatic nerve during SAPP are largely interferon (IFN)-γ-producing Th1 T cells (24, 
27). The major antigenic target of SAPP-causing T cells is myelin protein zero (P0) (24, 
26, 30, 96), a major component of the PNS myelin sheath. Disruption of central 
tolerance in NOD.AireGW/+ or ICAM-/- mice results in an altered T cell repertoire and 
increased escape of autoreactive P0-specific T cells into the periphery (24, 26). B cells 
also contribute to SAPP pathogenesis as genetic B cell deficiency and α-CD19 
treatment reduce SAPP severity in B7-2 deficient mice (28, 40). While DC, T cells, and 
B cells are all known contributors to SAPP pathogenesis, the contributions of additional 
immune cell types and nerve-resident cells are not clear.  
Complement has also been implicated in the pathogenesis of PNS autoimmunity 
(57, 58, 97) in addition to these cellular components of the immune system. C1q is the 
initiating component of the classical complement pathway. C1q is composed of three 
genes: C1q A, B, and C that assemble into a triple helix. Six triple helical strands form 
the intact C1q molecule, which has two functionally and structurally distinct domains: 
the globular domain, which recognizes pathogen and damage associated molecular 
patterns, and the collagen-like domain (52, 53), which can interact with CD49b (54, 55). 
In addition to activating the classical complement pathway, C1q functions to opsonize 
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apoptotic and necrotic debris, regulate DC maturation, and induce cytokine secretion, 
as well as other emerging functions (52, 53). For example, interaction between CD49b 
and C1q is required for interleukin (IL)-6 secretion by mast cells during infection (54). 
The pro- and anti- inflammatory functions of C1q have implicated C1q as a major player 
in autoimmune disease. In fact, C1q is upregulated in nerve tissue from CIDP patients 
(56) and increased activation of the complement pathway is associated with disease 
severity in CIDP (57).   
Schwann cells are not passive targets of autoimmune attack, but instead may 
also participate in the inflammatory response. Following nerve injury, Schwann cells 
undergo a process of dedifferentiation during which Schwann cells not only reacquire an 
immature phenotype, but also upregulate extracellular matrix proteins, autophagy 
machinery, and pro-inflammatory signals. Dedifferentiated Schwann cells serve several 
functions in the injured nerve including, myelin phagocytosis, axon protection, immune 
cell recruitment, and eventually remyelination (7, 16). In this study, we show that 
CD49b, a well-known marker of NK cells, is upregulated in the PNS during SAPP. 
Surprisingly, CD49b in the PNS is not expressed by NK cells or NK T cells, but by a 
non-hematopoietic cell type that expresses markers consistent with Schwann cells with 
an immature or dedifferentiated phenotype. Additionally, we show that Schwann cell-
associated CD49b co-localizes with complement factor C1q. The expansion of CD49b+ 
Schwann cells with an immature or dedifferentiated phenotype, and the association 
between CD49b and C1q in the sciatic nerve during SAPP suggest a potential role for 
CD49b/C1q in SAPP and CIDP pathogenesis.   
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2.2 Results 
 
2.2.1 T cells, macrophages, dendritic cells, and CD49b+ cells increase in frequency and 
number in the sciatic nerve during SAPP. 
  
We analyzed the cellular composition of the sciatic nerves from NOD.AireGW/+ 
mice after the appearance of signs and symptoms of SAPP using flow cytometry. Both 
the frequency and the total number of CD4+ and CD8+ T cells were significantly 
increased in SAPP mice compared to wild-type and non-neuropathic NOD.AireGW/+ mice 
(Figure 2.1A, B). In parallel, CD11b+ CD11c+ cells, and CD11c+ DC frequency and 
numbers were significantly increased in SAPP nerves compared to wild-type and non-
neuropathic NOD.AireGW/+ mice (Figure 2.1C, D). Almost all the CD11b+ CD11c+ cells 
expressed F4/80 indicating that the CD11b+ CD11c+ double positive population is 
largely composed of macrophages (Figure 2.1C). Overall, the most numerous immune 
cell populations in the sciatic nerve of neuropathic NOD.AireGW/+ mice were T cells and 
macrophages. 
Of note, a population of CD49b+ cells (stained with the antibody clone DX5) in 
the sciatic nerve was also significantly increased in frequency and total numbers during 
SAPP (Figure 2.1E-G). CD49b is a widely-used marker of NK T cells and NK cells (98), 
suggesting that these CD49b+ cells might represent NK and/or NK T cells. To 
characterize these cells, we immunolabeled for NKp46, a more specific NK cell marker 
(99), and CD3, a marker of NK T cells (100).  To determine whether differences 
observed between wild-type and neuropathic NOD.AireGW/+ mice were due to the 
development of neuropathy or were a general feature of NOD.AireGW/+ mice, we 
examined staining in wild-type and NOD.AireGW/+ mice before 10 weeks of age (prior to 
neuropathy onset) and after 15 weeks of age (following neuropathy onset). Surprisingly, 
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CD49b+ cells in the sciatic nerve of both wild-type and NOD.AireGW/+ mice lacked 
NKp46 both before 10 weeks of age and after 15 weeks of age (Figure 2.2A top) 
suggesting that CD49b+ cells in sciatic nerve were not NK cells. To ensure the quality of 
the NKp46 antibody, we also checked for NKp46 staining in splenocytes. NKp46+ 
CD49b+ NK cells were easily identifiable in splenocytes from both wild-type and 
NOD.AireGW/+ mice at both time points examined (Figure 2.2A bottom) confirming that 
the NKp46 antibody was working sufficiently. CD49b+ cells also lacked CD3 expression 
in both wild-type and NOD.AireGW/+ mice both before 10 weeks of age and after 15 
weeks of age (Figure 2.2B) suggesting that CD49b+ cells in the sciatic nerve are not NK 
T cells. Similarly to CD49b+ cells (Figure 2.1E-G), CD3- NKp46- CD49b+ cells expand 
in frequency (Figure 2.2C) and total numbers (Figure 2.2D) in NOD.AireGW/+ mice older 
than 15 weeks of age compared to NOD.AireGW/+ mice younger than 10 weeks of age 
and wild-type mice of either age group. Together these findings suggest that CD49b+ 
cells in the sciatic nerve are neither NK cells nor NK T cells. 
To determine whether CD49b+ cell expansion during neuropathy is specific to 
the NOD.AireGW/+ model or is a general feature of immune mediated neuropathies, we 
examined CD49b expression in the sciatic nerve during other models of neuropathy. 
Genetic depletion of B7-2 or antibody blockade of both B7-1 and B7-2 causes immune-
mediated neuropathy (27, 29). Examination of neuropathic α-B71/2-treated sciatic nerve 
revealed an expansion of CD3- NKp46- CD49b+ cells similar to that seen in 
NOD.AireGW/+ mice (Figure 2.3A). P0 is a major component of the myelin sheath in the 
PNS and is a major antigen driving autoimmunity in NOD.AireGW/+ mice (24). Peripheral 
neuropathy can also be induced via adoptive transfer of activated T cells isolated from 
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NOD.AireGW/+ mice (24) or P0-specific T cell transgenic mice (30) into NOD.SCID 
recipients. Recipients of activated T cells from either NOD.AireGW/+ mice (Figure 2.3B) or 
P0-specific T cell transgenic mice (Figure 2.3C) also showed expansion of CD3- 
NKp46- CD49b+ cells. The presence of CD3- NKp46- CD49b+ cells in multiple models 
of peripheral neuropathy suggests that expansion of these cells is a generalizable 
feature of autoimmune peripheral neuropathy. 
2.2.2 CD3- NKp46- CD49b+ cells are nerve resident cells.  
 
To determine whether the CD3- NKp46- CD49b+ cells are bone marrow derived, 
we stained for the hematopoietic cell marker CD45. CD3- NKp46- CD49b+ cells were 
negative for CD45 (Figure 2.4A) indicating that they are non-hematopoietic. In order to 
further test whether CD3- NKP46- CD49b+ cells are nerve resident or bone marrow 
derived cells, we transferred bone marrow from mice expressing GFP under the control 
of the actin promoter (actin-GFP) to irradiated NOD.AireGW/+ mice. Chimeric mice 
showed similar levels of GFP fluorescence in the spleen as the actin-GFP donor mice 
(Figure 2.4B). As expected, T cells in both the spleen and the sciatic nerve of chimeric 
mice were approximately 60% GFP positive. However, while CD3- NKp46- CD49b+ 
cells in the spleen were 60% GFP positive, in the nerve, only 2-3% of CD3- NKp46- 
CD49b+ cells were GFP+ (Figure 2.4C, D). This suggests that CD3- NKp46- CD49b+ 
cells in the nerve are not bone marrow-derived and are most likely nerve resident cells.  
CD49b has been reported to be expressed on epithelial cells, endothelial cells, 
and fibroblasts (101). We used flow cytometry to investigate whether the CD3- NKp46- 
CD49b+ cells observed in the sciatic nerve of NOD.AireGW/+ neuropathic mice were any 
of these cell types. Compared to cells isolated from ear tissue, CD3- NKp46- CD49b+ 
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cells in the nerve did not express the epithelial marker Epcam (102) (Figure 2.4E left). 
Similarly, CD3- NKp46- CD49b+ cells in the nerve lacked the endothelial (103) and 
endoneurial fibroblast marker (104) CD34 (Figure 2.4E) compared to splenic CD49b+ 
cells. Taken together our data suggest that CD3- NKp46- CD49b+ cells in the PNS of 
SAPP mice are nerve resident cells that are not epithelial cells, endothelial cells, or 
endoneurial fibroblasts. 
2.2.3 CD3- NKp46- CD49b+ cells express Schwann cell markers.  
 
We sorted CD49b+ cells from sciatic nerve tissue of SAPP mice and performed 
microarray analysis to determine the expression-profile of CD49b-expressing cells in the 
PNS. CD49b+ cells expressed numerous Schwann cell markers (Figure 2.5A) 
compared to CD11c+ DC and CD4+ T cells. Genes indicative of Schwann cell 
progenitors or immature Schwann cells (including Dhh, Erbb3, and Tfap2a), were 
among the most upregulated compared to CD11c+ DC and CD4+ T cells. However, 
genes indicative of fully mature myelinating Schwann cells such as Gjb1/connexin32, 
Pmp2, Mbp, and Egr2/Krox20, were more moderately expressed. Endoneurial 
fibroblasts, another common cell type in the PNS, have been reported to express Thy1 
and CD34. CD49b+ cells did not express either of these markers by microarray 
analysis. Similarly, CD49b+ cells did not express T cell-specific genes CD3, Lck, and, 
Zap70 or DC-specific genes CD11c (Itgax), cathepsin H (Ctsh), and CD86. The 
expression pattern of Schwann genes in the CD49b+ population suggests that CD49b+ 
cells may be a population of immature or dedifferentiated Schwann cells, which bear 
many of the same markers as immature Schwann cells.  
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Next, we performed flow cytometry to determine whether CD49b+ cells co-
express Schwann cell markers at the protein level. Immature Schwann cells express 
both S100b and p75. Myelinating Schwann cells downregulate p75 and maintain S100b 
expression while non-myelinating Schwann cells downregulate S100b and maintain p75 
expression (105). The CD49b+ cells in NOD.AireGW/+ neuropathic animals (Figure 2.5B, 
C) express both S100b and p75—more than 90% co-expressed S100b, and more than 
80% co-expressed p75—supporting the notion that CD49b+ cells are immature or 
dedifferentiated Schwann cells. Furthermore, CD49b co-localized with p75 when 
examined by immunofluorescence (Figure 2.5D). Our results show that CD49b, a well-
known marker for NK cells and NK T cells, is not expressed by NK or NKT cells during 
SAPP, but instead is expressed by an immature or dedifferentiated population of 
Schwann cells. 
2.2.4 CD49b in PNS colocalizes with complement factor C1q.  
 
CD49b has been shown to interact with the complement factor C1q through 
collagen-like domain (54, 55), and is upregulated in nerve from CIDP patients (56). This 
led us to hypothesize that CD49b on Schwann cells during SAPP may also interact with 
C1q. To examine this possibility, we immunostained cyrosections of sciatic nerves from 
wild-type and NOD.AireGW/+ neuropathic animals with α-C1q antibodies. C1q expression 
was not detectable in wild-type sciatic nerve, and was dramatically increased in sciatic 
nerve of SAPP mice (Figure 2.6A). Double-labeling for CD49b and C1q revealed that 
CD49b and C1q were partially co-localized to the same cells (Figure 2.6B), supporting 
the possibility that C1q may interact with CD49b in the SAPP.  
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2.3 Discussion 
 
In this study, we show that CD49b, a well-known marker for NK cells and NK T 
cells, is upregulated in several murine models of SAPP, indicating that CD49b 
upregulation may be a general feature of autoimmune neuropathies. Unexpectedly, 
CD49b was not expressed by NK or NKT cells, but was instead expressed by non-
hematopoietic nerve-resident cells, which we determined to be immature or 
dedifferentiated Schwann cells. Finally, CD49b co-localized with the complement factor 
C1q in sciatic nerve from SAPP mice indicating that CD49b itself may participate in the 
pro-inflammatory process through binding to C1q. 
Our results indicate that dedifferentiated Schwann cells express CD49b in SAPP 
nerves; there was comparatively little expression in normal nerve. Schwann cell 
expression of CD49b/integrin α2 has not previously been described in mice. Schwann 
cell express numerous integrins, including CD49b, in humans (73, 101) and rat (71) 
(72).  In normal human nerve, CD49b expression is restricted to non-myelinating 
Schwann cells (73); however, in normal rat nerve, CD49b is also expressed by 
myelinating Schwann cells (71). In a rat model of experimental autoimmune neuritis 
(EAN), a model of human Guillain-Barré syndrome (GBS), CD49b expression 
decreases during the acute phase of disease and rebounds during the recovery phase, 
but a corresponding fall was not found in nerve biopsies from GBS patients (71). The 
difference in CD49b modulation during SAPP in mice compared to EAN in rats and GBS 
in humans could be related to differences between these species or in the diseases 
themselves. EAN is induced via immunization with myelin proteins, whereas SAPP 
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pathogenesis occurs due to breakdown of T cell central tolerance, and the pathogenesis 
of human GBS and CIDP are the subjects of ongoing investigations (106) , (107). 
The function of increased CD49b in SAPP is unclear. CD49b specifically 
heterodimerizes with integrin β1, which is required for axonal sorting and proper myelin 
formation during development (108). This effect depends on α6, and α7, but not α3-
containing integrin β heterodimers (109); however, the potential role α2 (CD49b), and 
α1-containing integrin β1 heterodimers has not been investigated. Because CD49b 
interacts with complement factor C1q (54), we looked for and found increased 
expression of C1q in sciatic nerve of SAPP mice that co-localized with CD49b 
expression. This suggests a potential role for CD49b in modulating the immune 
response during SAPP and CIDP, in which C1q mRNA expression is increased (56). 
C1q inhibition protects mice from acute motor axonal neuropathy, a variant of GBS (97), 
and our data motivates further investigations on the role of CD49b and C1q in CIDP. 
2.4 Methods 
 
2.4.1 Animals 
 
 Strains and housing. Mice were housed in a specific pathogen-free facility at the 
University of North Carolina at Chapel Hill (UNC-CH). All animal experiments were 
performed in compliance with the Animal Welfare Act and the National Institute of 
Health (NIH) guidelines for the ethical care and use of animals in research. 
NOD.AireGW/+ and myelin protein zero T cell receptor transgenic (NOD.P0T) mice were 
generated as previously described (25, 30). NOD.SCID mice were purchased from the 
Jackson Laboratory. Mice expressing GFP under the control of the actin promoter (GFP 
mice) were a kind gift of Roland Tisch. 
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 Adoptive transfer model: 48-well plates were coated with α-CD3 (eBioscience 
clone 145-2C11; 1 µg/ml in PBS) and α-CD28 (BD Pharmingen clone 37.51; 1 µg/ml in 
PBS) overnight at 4°C or for at least 2 hours at 37°C and washed with PBS. 
Splenocytes from neuropathic NOD.AireGW/+ or NOD.P0T mice were plated at a density 
of 106 (NOD.AireGW/+) or 5 x 105 (P0T) cells/well and were cultured for 96-120 hours in 
DMEM supplemented with 10% fetal bovine serum, 10 mM HEPES buffer (NOD.P0T 
mice only), Penicillin-Streptomycin (100U/mL, Gibco), and 2-mercaptoethanol (55 µM). 
1X106 activated splenocytes were harvested, washed with sterile PBS, and adoptively 
transferred in sterile PBS using retro-orbital injection into immunodeficient NOD.SCID 
recipients sedated with 2% isoflurane in oxygen. 
 α-B71/2 induced neuropathy: α-B7-1 and α-B7-2 antibodies were used to induce 
peripheral neuropathy as previously described(27). Briefly, 50µg of each antibody was 
administered every other day for 10 treatments starting at postnatal day 14. 
Evaluation of SAPP: Mice were evaluated weekly (spontaneous model) or every other 
day (adoptive transfer model) for clinical signs of neuropathy, which was scored as 
follows: 0- no signs of neuropathy present, 1-mild hind limb weakness, 2-pronounced 
bilateral hind limb weakness, 3-reduced or absent ability to grip cage grating, 4-
moribund. SAPP was confirmed by electromyography, which was performed as 
previously described (27, 110). 
2.4.2 Flow Cytometry 
 
 Support. All flow cytometry experiments were carried out with the support of the 
UNC Flow Cytometry Core Facility. The UNC Flow Cytometry Core Facility is supported 
in part by P30 CA016086 Cancer Center Core Support Grant to the UNC Lineberger 
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Comprehensive Cancer Center. Research reported in this publication was supported in 
part by the North Carolina Biotech Center Institutional Support Grant 2012-IDG-1006 
and by the Office of the Director. The content is solely the responsibility of the authors 
and does not necessarily represent the official views of the NIH. 
 Nerve digestion: Nerves were chopped with a razor blade and digested in PBS 
containing 1mg/ml collagenase and 1% FBS at 37°C for 30 minutes with periodic 
agitation. Part-way through the digestion, the sample was triturated with a 20g needle to 
aid in tissue disruption. Dissociated nerves were filtered through 40 µm mesh and 
washed prior to use in experiments.   
 Antibodies: CD3 (Clone 145-2C11), CD4 (Clone RM4-5), CD8 (clone 53-6.7), 
F4/80 (Clone BM8), CD11c (Clone N419), Gr-1 (Clone RB6-8C5), CD49b (Clone DX5), 
NKp46 (Clone 29A1.4), CD45 (Clone 30F11), CD80 (Clone 16-10A1), and CD86 (Clone 
GL1) antibodies were purchased from eBioscience. CD11b (Clone M1/70), Thy1 (Clone 
53-2.1), MHCII (Clone OX-6), CD34 (Clone RAM34), FcεRIa (Clone MAR-1), and 
CD200R3 (Clone Ba13) antibodies were purchased from BioLegend. PDGFR, epcam 
(Clone G8.8), live/dead fixable yellow dye (Life Technologies) was used to exclude 
dead cells. 
 Staining. Single cell suspensions were washed twice with FACS buffer. Fc 
receptors were blocked by incubating cells with supernatant from a 2.4G2 hybridoma. 
Cells were stained for 30 minutes on ice and washed prior to analysis. 
 Analysis: Samples were run on Beckman Coulter CyAn ADP or Becton Dickinson 
LSRII flow cytometers and analyzed using FlowJo software.  
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2.4.3 Bone Marrow Chimera 
 
Bone marrow was isolated from NOD.GFP+ or wild-type NOD mice. Viable cells 
were purified from the bone marrow using lympholyte-M (Cedarlane) according to 
manufacturer’s instructions. Rabbit complement (Cedarlane) was used to lyse CD4 
(Clone GK1.5) and CD8 (YTS169) labeled cells according to manufacturer’s 
instructions. Bone-marrow was transferred into lethally irradiated (850 rads from and X-
ray source) NOD.AireGW/+GFP+ or NOD.AireGW/+ recipients. 
2.4.4 Microarray 
 
CD4+, CD11c+, and CD3-DX5+ cells were flow sorted from sciatic nerve tissue 
of neuropathic NOD.AireGW/+ mice using a Becton Dickenson FACSAria II with the 
assistance of the UNC Flow Cytometry Core Facility. For samples with fewer than 
10,000 cells (CD3-DX5+), Agilent Absolutely RNA Nanoprep Kit was used to isolate 
RNA according to the manufacturer’s instructions. For samples with more than 10,000 
cells Qiagen RNeasy Plus Mini kit was used for RNA isolation. RNA quality was 
assessed by bioanalyzer. The Nugen One-Direct kit was used to prepare amplified 
cDNA and samples were run on an Affymetrix Mouse Gene 2.1 ST Array. Data was 
analyzed using Partek Genomics Suite. RNA quality analysis, cDNA synthesis, and 
microarray were performed by the UNC Genomics Core. 
2.4.5 Immunofluorescence staining 
 
 Nerve sections: 15-20 week neuropathic NOD.AireGW/+ and wild-type mice were 
perfused with 4% paraformaldehyde (PFA) in phosphate buffered saline (PBS) and 
post-fixed in 4% PFA for 2-4 hours. Sciatic nerve tissue was infiltrated in 10% sucrose 
in PBS prior embedding in OCT medium. Frozen sciatic nerve sections (8 μm) were 
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washed in PBS containing 0.1% Tween20 (PBST) and blocked in 10% normal goat 
serum in PBST for 1 hr at room temperature. Primary antibodies were diluted in 3% 
bovine serum albumin in PBST, and sections were stained with rat α-mouse CD49b 
(clone DX5; BioLegend; 1:100), rabbit α-P75 (Abcam; 1:500), or rabbit α-C1q (Abcam; 
1µg/ml) at 4°C overnight. The sections were washed in PBST and incubated with 
DyLight594-conjugated goat α-rat IgM (Thermo Fisher; 1:500) or DyLight 488-
conjugated goat α-rabbit IgG (Thermo Fisher; 1:500) for 2 hr at room temperature. 
Slides were washed in PBST and mounted in SouthernBiotech Dapi-Fluoromount-G. 
Slides were imaged using Zeiss LSM 710 or 780 confocal microscopes. 
2.4.6 Statistics 
 
Statistics were performed with GraphPad Prism software or Partek Genomics 
Suite (Microarray).  
26 
 
 
Figure 2. 1: T cells, macrophages, dendritic cells, and CD49b+ cells increase in 
frequency and number during SAPP. Sciatic nerves from NOD wild-type and 
NOD.AireGW/+ animals was analyzed by flow cytometry at less than 10 weeks and 
greater than 15 weeks of age, before and after the onset of SAPP, respectively.  
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A) Representative flow plots showing CD3 (top) and CD4 versus CD8 staining (bottom). 
The CD4 versus CD8 plot was pre-gated on CD3+ events. B) Quantification of the 
frequency (left) and total numbers (right) of T cells within the whole sciatic nerve.  
C) Representative flow plots showing CD11c versus CD11b (top) and F4/80 (bottom) 
staining. F4/80 histograms were pre-gated on CD11c+ (grey shaded) or CD11b+ 
CD11c+ (black line) populations. D) Quantification of the frequency (left) and total 
numbers (right) of CD11b+ CD11c+, and CD11c+ populations within whole sciatic 
nerve. E) Representative histograms showing CD49b staining. F) Quantification of the 
frequency (left) and total numbers (right) of CD49b+ cells within whole sciatic nerve.  
G) Immunofluorescence staining of CD49b in sciatic nerve longitudinal sections. 
Numbers on flow plots represent the frequency of events in the gate. * indicates p<0.05 
by one way ANOVA with multiple comparisons.  
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Figure 2. 2: CD49b+ cells in SAPP are not NK T cells or NK cells. Sciatic nerves 
from NOD wild-type and NOD.AireGW/+ animals was analyzed by flow cytometry at 
less than 10 weeks or greater than 15 weeks of age. A) Representative flow plots 
showing CD49b versus NKp46 staining in sciatic nerve (top) and spleen (bottom).  
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B) Representative flow plots showing CD49b versus CD3 staining in sciatic nerve.  
C) Frequency and D) total number of CD3- NKP46- CD49b+ cells in sciatic nerve. 
Numbers on flow plots represent the frequency of events in the gate. * indicates 
p<0.005 by one way ANOVA. 
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Figure 2. 3: CD3-NKp46-CD49b+ cells expand in multiple models of autoimmune 
peripheral neuropathy. Representative flow plots showing CD3 versus CD49b staining 
in sciatic nerve of multiple models of peripheral neuropathy. A) Peripheral neuropathy 
induced by α-B71/2 treatment. B) Neuropathy induced by adoptive transfer of activated 
NOD.AireGW/+ splenocytes. C) Neuropathy induced by adoptive transfer of P0-specific T 
cells. Numbers on flow plots represent the frequency of events in the gate.  
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Figure 2. 4: CD49b+ cells are nerve-resident cells. A) Representative histograms 
showing CD45 expression on CD3-NKP46-CD49b+ cells (black line) and CD3+ T cells 
(grey shaded) in sciatic nerve of SAPP mice. B) Experimental design of bone marrow 
transplant. Representative flow plots showing GFP expression in donor and recipient 
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splenocytes. C) Representative flow cytometric plots showing GFP expression in T cells 
(top) and CD49b+ cells (bottom) isolated from neuropathic bone marrow chimeric mice 
described in B. D) Frequency of GFP positivity in CD49b+ and CD3+ cells from bone 
marrow chimeric mice described in B. E) Representative histograms showing 
expression of Epcam on ear skin cells compared to CD3-NKP46-CD49b+ cells from the 
sciatic nerve (left) and CD34 on CD3-NKP46-CD49b+ cells isolated from either spleen 
or sciatic nerve (right). Numbers on flow plots represent the frequency of events in the 
gate. * indicates p<0.05 by one way ANOVA. 
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Figure 2. 5: CD49b+ cells are Schwann cell-like. A) Heat map showing expression of 
genes associated with Schwann cells, endoneurial fibroblasts (EF), T cells, and DC in 
CD49b+ cells compared to CD11c+ and CD4+ cells isolated from SAPP nerve.  
B) Representative flow plots showing S100b (top) and p75 (bottom) expression in 
CD49b+ cells in WT compared to SAPP mice. Numbers on flow plots represent the 
frequency of events in the gate. C) Quantification of the frequency of S100 (left) and 
p75 (right) positivity within the CD49b+ population.  D) Co-localization of CD49b and 
p75 in sciatic nerve cryosections from wild-type and SAPP mice. The area outlined in 
the middle panel is enlarged in the bottom panels. 
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Figure 2. 6: C1q is expressed in neuropathic sciatic nerve and co-localizes with 
CD49b. Immunostained cryosections from WT and neuropathic NOD.AireGW/+ sciatic 
nerves. A) C1q immunofluorescence in wild-type and neuropathic NOD.AireGW/+ mice. 
B) Co-localization of CD49 and C1q in sciatic nerve of NOD.AireGW/+ mice. The outlined 
area is enlarged in the bottom panel. 
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CHAPTER 3: SCHWANN CELL-DERIVED PERIOSTIN PROMOTES AUTOIMMUNE 
PERIPHERAL POLYNEUROPATHY VIA MACROPHAGE RECRUITMENT2 
 
3.1 Introduction 
 
Chronic inflammatory demyelinating polyneuropathy (CIDP) and acute 
inflammatory demyelinating polyneuropathy (AIDP, a form of Guillain-Barre syndrome; 
GBS) are characterized by sensory impairment and disabling weakness (111, 112) and 
are the result of autoimmune demyelination of the peripheral nervous system (PNS). 
Current therapies include plasmapheresis and intravenous immunoglobulin (IVIg) for 
CIDP and AIDP as well as corticosteroids for CIDP, all of which have non-specific 
mechanisms of action and broadly suppress the immune system (113, 114). CIDP 
patients often require long-term treatment in order to maintain therapeutic effect (113), 
and even with these treatments, clinical remission is not achieved in ~30% of patients 
(4). Thus, the development of novel, mechanism-based therapies is desirable and 
would be greatly aided by the delineation of pathogenic mechanisms. 
Through the use of mouse models of inflammatory neuropathies and patient 
biopsy samples, the immune mechanisms that contribute to the development of 
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autoimmune peripheral neuropathy have been partially illuminated. The prominence of 
T cells and F4/80+ macrophages in affected nerves of spontaneous autoimmune 
peripheral polyneuropathy (SAPP) mice (24, 29), experimental allergic neuritis (EAN) 
mice (115, 116), and human patients (2, 23) suggests that these cells are particularly 
important. Further, in SAPP and EAN, CD4+ T cells isolated from neuropathic mice are 
sufficient to transfer disease to T and B cell-deficient (SCID) recipients, underscoring an 
important role for CD4+ T cells among lymphocytes (24, 96, 117). Both Th1 and Th17 
have been implicated in the pathogenesis of CIDP and GBS since the frequency of Th1 
and Th17 cells is elevated in blood and CSF of patients (118, 119), but the relative 
importance of Th1 and Th17 is still controversial. In models of SAPP, Th1 T cells 
predominate (24, 96) but in EAN an important role for Th17 has also been suggested 
(120). Macrophages may also contribute to autoimmune destruction of the PNS, since 
macrophages in EAN exhibit an inflammatory phenotype, which includes the secretion 
of pro-inflammatory factors such as reactive oxygen species and the cytokines 
interleukin (IL) 12, tumor necrosis factor-alpha (TNFa), and IL-6 (31). The signals that 
recruit CD4+ T cells and macrophages into the PNS in inflammatory neuropathies, 
however, are currently unclear. 
The extracellular matrix (ECM) is a prominent feature of the PNS, and has been 
implicated in numerous developmental processes, including Schwann cell migration, 
radial sorting of axons, and myelination (60, 121). In light of recent reports that find a 
role for ECM proteins in inflammation (81, 82, 90, 92, 122), we investigated their 
possible role in the development of SAPP (24). We found increased expression of the 
ECM protein periostin (Postn) by Schwann cells in affected nerves of SAPP mice and 
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CIDP patients. Moreover, Postn expression aggravates neuropathy since Postn-
deficient animals have delayed disease onset and improved nerve function by both 
electrophysiological and pathological analysis. Additionally, Postn-deficient sciatic 
nerves show reduced infiltration of both T cells and macrophages. Macrophages, but 
not T cells, migrated across a transwell membrane in response to Postn, suggesting 
that Postn primarily induces macrophage chemotaxis. Finally, macrophages recruited to 
affected sciatic nerves are pathogenic, as macrophage-depleted animals showed 
delayed disease onset and improved nerve function. Overall, our results demonstrate 
that Schwann cell-derived Postn promotes neuropathy pathogenesis by directly 
recruiting pathogenic macrophages to the PNS.   
3.2 Results 
 
3.2.1 Postn expression is induced during SAPP.  
 
 To investigate a possible role for ECM proteins in the development of 
inflammatory neuropathy, we used a strain of NOD mice that develops SAPP owing to a 
dominant, loss-of-function G228W mutation in the Autoimmune Regulator gene 
(NOD.AireGW/+ mice) (24). PNS autoimmunity in NOD.AireGW/+
 
mice shares key features 
with human CIDP, including infiltration of peripheral nerves by CD4+ T cells and F4/80+ 
macrophages (123-125), interferon gamma (IFNg) production by CD4+ T cells (126, 
127), and peripheral nerve demyelination (24, 128). We screened mRNA levels of 6 
ECM genes with known roles in PNS development: laminin a2 (Lama2) (65), laminin a4 
(Lama4) (65), laminin a5 (Lama5) (129), laminin b1 (Lamb1) (65), thrombospondin 2 
(Thbs2)(130), and Postn (85, 94). Relative expression levels of these genes were 
compared between sciatic nerves from age-matched, wildtype (NOD.WT) mice vs. 
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affected NOD.AireGW/+ mice by qRT-PCR. Sciatic nerves from NOD.AireGW/+ mice were 
harvested when severe neuropathy (clinical score 3 out of maximum 4) was observed. 
While the levels of Lama2, Lama4, Lama5 and Lamb1 mRNA showed no change 
(Figure 3.1A-D), those of Thbs2 and Postn were significantly increased in neuropathic 
NOD.AireGW/+ mice compared to NOD.WT mice (Figure 3.1E,F). Increased Thbs2 
expression with PNS inflammation was not surprising, given previous reports that Thbs2 
expression increases after nerve injury, and Thbs2 may play a role in axonal 
regeneration (131). However, increased Postn expression was unexpected since it has 
not been previously linked to peripheral nerve injury or inflammation.  
A member of the fasciclin family, Postn is widely expressed during embryonic 
development (94, 132-135). Postn promotes cell motility through interaction with 
integrins (87, 88), and has been linked to several inflammatory diseases (81-83, 92), 
making it an intriguing target to investigate. Increased Postn expression is associated 
with neuropathy since 8-week old, pre-neuropathic mice expressed similar levels of 
Postn mRNA compared to NOD.WT mice (Figure 3.2). To examine Postn expression in 
SAPP, we used Western blot and immunostaining to characterize Postn protein 
expression in the PNS of neuropathic mice. Western blot showed significantly increased 
Postn protein in whole sciatic nerves from neuropathic NOD.AireGW/+ mice compared to 
those from NOD.WT mice (Figure 3.1G, H). We verified that this 75 kDa band 
corresponded to Postn since it was absent in Postn-deficient mice (Figure 3.2). 
Immunostaining showed Postn-immunoreactivity mostly restricted to the perineurium of 
NOD.WT nerves (Figure 3.1I, top left panel), whereas Postn-immunoreactivity was also 
diffusely positive in the endoneurium of affected NOD.AireGW/+ nerves (Figure 3.1I, top 
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right). Thus, Postn mRNA and protein expression is increased in neuropathic 
NOD.AireGW/+ nerves. 
To determine whether increased Postn expression is specific to NOD.AireGW/+ 
mice, we immunostained sciatic nerves from two additional models of inflammatory 
neuropathies: autoimmune peripheral neuropathy induced in immunodeficient SCID 
mice upon transfer of splenocytes from neuropathic NOD.AireGW/+ mice (24), and 
transfer of CD4+ T cells from a myelin protein zero (Mpz or P0)-specific T cell receptor 
transgenic mouse line (NOD.POT TCR Tg) (30). Reconstituted mice were sacrificed 
when severe neuropathy (clinical score 3) was observed. By immunohistochemistry, 
Postn expression in sciatic nerves was increased in both of these models (Figure 3.1I, 2 
bottom panels), suggesting that induction of Postn is not unique to NOD.AireGW/+ mice, 
but is a more generalizable feature of inflammatory peripheral neuropathies in mice. 
Interestingly, we observed no change in the expression of Postn three days post 
axotomy (Figure 3.4), suggesting that Postn upregulation in the PNS may be specific to 
inflammatory neuropathies. Finally, to determine whether Postn is upregulated in human 
CIDP, we immunostained nerve biopsies from 5 CIDP patients and 5 patients with 
axonal (non-inflammatory) neuropathy. Postn was observed in 2/5 CIDP patient 
samples, but was not observed in samples from patients with axonal neuropathy (Figure 
3.1J). Therefore, Postn upregulation is a feature of inflammatory neuropathy in both 
mice and humans.       
3.2.2 Schwann cells express Postn during SAPP.  
 
 To identify the cells expressing Postn, we generated NOD Postn reporter mice, 
which harbor a Postn allele into which a lacZ cassette is targeted (136). Histochemistry 
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for beta-galactosidase using X-gal as a substrate (137) was performed on nerves from 
neuropathic NOD.AireGW/+ and age-matched NOD.WT mice that were heterozygous for 
this Postn allele (PostnlacZ/+). In NOD.WT PostnlacZ/+ mice, X gal crystals were restricted 
to the perineurium of sciatic nerves (Figure 3.5A, top left panel), but in severely (clinical 
score 3) neuropathic NOD.AireGW/+ PostnlacZ/+ mice, X gal crystals were also prominent 
in the endoneurium (Figure 3.5A, B, top panels). In parallel, we used adoptive transfer 
(AT) of splenocytes from neuropathic NOD.AireGW/+ mice to induce neuropathy in T and 
B cell-deficient NOD.SCID PostnlacZ/+ recipients; in reconstituted mice, non-T and non-B 
cell lineages derived from NOD.SCID hosts harbor the Postn reporter allele. NOD.SCID 
PostnlacZ/+ recipient sciatic nerves were examined when severe neuropathy (clinical 
score 3) was observed and were compared to un-reconstituted NOD.SCID Postnlacz/+ 
control mice. In the AT model, beta-galactosidase activity was observed in a similar 
pattern to the spontaneous NOD.AireGW/+ model. Namely, in unreconstituted, non-
neuropathic control mice, beta-galactosidase activity was absent in the endoneurium 
and only seen in the perineurium. On the other hand, in reconstituted, neuropathic 
recipients, beta-galactosidase activity was present in the endoneurium (Figure 3.5A, B, 
bottom panels), confirming that endoneurial Postn expression is associated with 
neuropathy development and demonstrating that non-lymphocytes expressed Postn.  
Light microscopy of semi-thin sections of epoxy-embedded nerves from both 
neuropathic NOD.AireGW/+ and NOD.SCID Postnlacz/+ AT recipients revealed diffuse 
endoneurial beta-galactosidase activity as well as areas of intense beta-galactosidase 
activity (Figure 3.5B). We next used electron microscopy (EM) to characterize the cell 
types expressing Postn in the endoneurium of neuropathic nerves. EM showed that X-
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gal crystals were found in neuropathic NOD.AireGW/+ Schwann cells, inferred by their 
physical relationships with axons (Figure 3.5C,D, top panels). A similar pattern was 
seen in nerves from reconstituted, neuropathic NOD.SCID PostnlacZ/+ recipients (Figure 
3.5C,D, bottom panels; and 3.5E). X-gal crystals were seen in pro-myelinating Schwann 
cells that ensheathed large axons (Figure 3.5C), non-myelinating Schwann cells 
associated with many small, unmyelinated axons (Figure 3.5D), and normal appearing, 
myelinating Schwann cells (Figure 3.5E). X-gal crystals were also seen in endoneurial 
cells with features distinct from Schwann cells (Figure 3.6). To rule out the possibility 
that X-gal crystals were a non-specific staining artifact independent of the lacZ 
transgene, we performed histochemistry for beta-galactosidase on NOD.SCID mice 
lacking the PostnlacZ reporter. Nerve sections from NOD.SCID Postn+/+ recipients did not 
exhibit X-gal crystals, even in regions with reduced numbers of myelinated axons 
(Figure 3.7), demonstrating that X-gal crystals are specific to the lacZ transgene. 
Together, these findings indicate that X-gal crystals seen in Schwann cells and non-
Schwann endoneurial cells of neuropathic NOD.AireGW/+ mice reflect Postn reporter 
expression. 
To confirm that Schwann cells are a source of increased Postn expression in 
neuropathic nerves, we measured relative Postn mRNA expression by qRT-PCR in 
flow-sorted live CD45- CD3- p75+ (p75+) Schwann cells (gating strategy in Figure 3.8). 
In NOD.WT mice, in which neuropathy is absent, this population consists of non-
myelinating Schwann cells (138). In neuropathic NOD.AireGW/+ mice, on the other hand, 
this population likely also contains denervated (139, 140) and promyelinating (141) 
Schwann cells in addition to the normal non-myelinating Schwann cells.  In line with our 
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EM results, p75+ Schwann cells from neuropathic NOD.AireGW/+ mice expressed 
significantly more Postn mRNA than did p75+ Schwann cells isolated from NOD.WT 
animals (Figure 3.5F). Since X-gal crystals were also observed in non-Schwann cells 
(Figure 3.6), we also measured Postn expression by qRT-PCR in CD3+ T cells and 
CD11b+ macrophages isolated from the sciatic nerve of neuropathic NOD.AireGW/+ 
mice. Neither CD3+ T cells nor CD11b+ macrophages expressed Postn (Figure 3.5F). 
Thus, we conclude that Schwann cells induce Postn expression in mouse models of 
inflammatory neuropathies and are the main source of Postn in the sciatic nerve during 
neuropathy, whereas CD3+ T cells and CD11b+ macrophages do not express Postn.  
While our data indicate that murine Schwann cells produce Postn during 
neuropathy, the cellular source of Postn in CIDP patients is still unclear. To determine 
whether human Schwann cells are the source of Postn in CIDP patients, we 
immunofluorescently labeled CIDP patient biopsies with antibodies against Postn and 
the Schwann cell marker S100b (Figure 3.5G). Prominent overlap was observed 
between Postn and S100b indicating that Schwann cells are the source of Postn in 
human CIDP patients as well as mouse SAPP. As a complementary approach, we 
sought to determine whether a human Schwann cell line can be induced to express 
Postn. It has been reported that Neuregulin 1 (NRG1) and transforming growth factor 
beta (TGFb) can induce Postn expression in cultured rat Schwann cells (85). Further, 
TGFb is highly expressed in sciatic nerve of SAPP mice (Figure 3.9), suggesting its 
presence at the site of inflammation. Moreover, infiltrating CD4+ T cells express high 
levels of TGFb (data not shown). Based on these data, we cultured immortalized human 
Schwann cells (HSC) in the presence of NRG1, TGFb, or both NRG1 and TGFb and 
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measured Postn expression by qPCR (Figure 3.5H). Postn expression was increased 3-
fold in HSC treated with TGFb or TGFb and NRG1, but not in HSC treated with NRG1 
alone. These data indicate that TGFb induces Postn expression in human Schwann 
cells and support the notion that Schwann cells are the source of increased Postn in 
CIDP.   
3.2.3 Postn deficiency delays the onset of neuropathy.  
 
 Mice homozygous for the Postn lacZ reporter allele also lack functional Postn 
expression because the beta-galactosidase cassette replaces exons 4-10 of the Postn 
gene (136). Thus, NOD.PostnlacZ/lacZ mice are effectively Postn “knockouts” (hereafter 
referred to as NOD.Postn-/-). Although Postn is expressed in the PNS during embryonic 
development, it has been reported that Postn-deficient mice have normal PNS function 
(85) demonstrating that Postn is dispensable for PNS development. Consistent with 
this, we saw no overt signs of PNS impairment in NOD.Postn-/- mice when assessed 
clinically (Figure 3.10A), electrophysiologically (Figure 3.10B-E), or anatomically (Figure 
3.10F-H). Thus, genetic Postn deficiency in mice does not alter PNS structure or 
function, or preclude the use of Postn-deficient mice to probe Postn’s role in PNS 
autoimmunity. 
 To undertake these studies, we used the AT model of inflammatory neuropathy 
in which splenocytes from Postn-sufficient, neuropathic NOD.AireGW/+ mice were 
transferred into Postn-deficient NOD.SCID recipients (NOD.SCID Postn-/-). 
Reconstituted recipients were Postn deficient in non-T and B cell types (including 
Schwann cells) since NOD.SCID Postn-/- recipients lack T and B cells. Splenocyte 
transfer provoked neuropathy in >90% of Postn-sufficient (NOD.SCID Postn+/+ or 
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NOD.SCID Postn+/-) recipients by 12 weeks after transfer (Figure 3.11A). Neuropathy 
incidence was not different between Postn wildtype (NOD.SCID Postn+/+) and 
heterozygous (NOD.SCID Postn+/-) recipients (Figure 3.12), suggesting that 
heterozygosity for the mutant Postn allele does not have a functional consequence. In 
contrast, NOD.SCID Postn-/- recipients were protected from neuropathy since 
splenocyte transfer provoked neuropathy in only 40% of NOD.SCID Postn-/- recipients 
by 12 weeks after transfer (Figure 3.11A). Thus, Postn deficiency in non-T and B cells 
ameliorates clinical neuropathy. 
 To characterize PNS disease in these mice further, we performed EMG on 
recipients at 10 weeks post AT, or earlier, if moderate/severe neuropathy (clinical score 
3) was noted. The 10 week time point was chosen because most Postn-sufficient 
recipients develop neuropathy by this time. EMG revealed that Postn-sufficient 
recipients had significantly reduced CMAP peak amplitudes (Figure 3.11B,C), slower 
conduction velocities (Figure 3.11D), and increased CMAP duration (Figure 3.11B,E) 
compared to NOD.SCID Postn-/- recipients at 10 weeks post AT. The combination of 
increased CMAP durations and reduced conduction velocities suggested that more 
axons are demyelinated in the Postn-sufficient recipients. To investigate this point, we 
examined sciatic nerves by light (semi-thin sections) and electron (thin sections) 
microscopy, and found larger regions of demyelinated axons in Postn-sufficient 
compared to deficient recipients (Figure 3.11F, H). In order to quantify demyelination, 
we compared the density of myelinated axons in tibial nerve cross sections. As 
expected, the number of myelinated axons/1000 µm2 was significantly lower in Postn-
sufficient AT recipient mice compared to Postn-deficient mice (Figure 3.11G). In 
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addition to demyelination, other factors such as edema and immune cell infiltration may 
contribute to the decreased myelinated nerve density observed in neuropathic animals. 
Indeed, the regions of demyelinated axons contained many cells that were not 
surrounded by a basal lamina and had the ultrastructural features of macrophages and 
lymphocytes. To investigate this issue further, we stained paraffin sections of sciatic 
nerves with hematoxylin/eosin and observed decreased cellular infiltration of sciatic 
nerves in NOD.SCID Postn-/- recipients as compared to Postn-sufficient recipients 
(Figure 3.11I, J).  
 We next used flow cytometry to determine the cellular composition of sciatic 
nerves in reconstituted Postn-sufficient vs. deficient recipients. We found decreased 
frequency and fewer absolute numbers of infiltrating CD45+ hematopoietic cells in 
sciatic nerves of NOD.SCID Postn-/- recipients compared to Postn-sufficient recipients 
(Figure 3.13A-C), confirming decreased immune cell infiltration with Postn-deficiency. 
To determine whether Postn deficiency alters the cellular composition of immune cell 
infiltration, we compared the frequencies of CD3+ T cells and F4/80+ macrophages 
within the nerves. We have previously reported that T cells and macrophages account 
for the majority of infiltrating cells in neuropathic NOD.AireGW/+ mice (24). Similarly, 
immunohistochemical staining of sciatic nerve sections from reconstituted, neuropathic 
NOD.SCID recipients of transferred NOD.AireGW/+ splenocytes showed increased CD3+ 
T cells and F4/80+ macrophages (Figure 3.14). The frequency and absolute numbers of 
both CD3+ T cells (Figure 3.13D-F) and CD11b+ F4/80+ macrophages (Figure 3.13G-I) 
were reduced in reconstituted NOD.SCID Postn-/- recipients compared to their Postn-
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sufficient counterparts. Thus, we conclude that neuropathy-resistance in Postn-deficient 
recipients is associated with less demyelination and decreased immune cell infiltration. 
3.2.4 Postn promotes macrophage chemotaxis.  
 
 Reduced T cell and macrophage numbers in the sciatic nerve of Postn deficient 
AT recipients could be the result of reduced proliferation, reduced T cell activation, or 
increased cell death. If Postn deficiency impacts T cell or macrophage proliferation or 
death, one would expect to see fewer T cells and macrophages in the spleen of Postn-
deficient mice. However, no difference was observed in the frequency or total number of 
CD3+ T cells, CD4+ or CD8+ T cells, or CD11b+ macrophages (Figure 3.15). 
Additionally, the frequency and number of Ki67+ T cells (Figure 3.16A-C) and 
macrophages (Figure 3.16D-F) were similar in NOD.Postn+/+ and NOD.Postn-/- mice 
suggesting that Postn deficiency does not impact T cell or macrophage proliferation. 
Similarly, no difference was observed in the frequency or number of effector/memory 
(CD44+ CD62L-) CD4+ T cells in Postn deficient mice compared to Postn sufficient 
mice (Figure 3.16G-K). Finally, no difference in the expression of the apoptotic regulator 
Bcl-2 was observed in macrophages treated in vitro with Postn (Figure 3.17). Taken 
together these data suggest that reduced T cells and macrophages in the sciatic nerve 
of Postn-deficient AT recipients cannot be explained by altered immune cell 
proliferation, activation, or death. 
Another possible explanation for decreased T cell and macrophage nerve 
infiltration in Postn-deficient mice is that Postn normally promotes migration of these 
immune cell types into the PNS. We used a transwell system (Figure 3.18A) to test the 
ability of CD4+ T cells or macrophages to migrate toward increasing concentrations of 
48 
 
Postn protein. Postn failed to induce migration of CD4+ T cells that were isolated from 
spleen of neuropathic NOD.AireGW/+ mice, regardless of the concentration of Postn 
(Figure 3.18B). However, migration of RAW cells, a macrophage-derived cell line, was 
increased in response to Postn in a dose-dependent manner (Figure 3.18C). Similar 
results were observed when NOD.AireGW/+ bone marrow-derived macrophages were 
used in place of RAW cells (Figure 3.18D). Known Postn receptors include integrins 
ItgaV (87) and ItgaM (CD11b) (88), which have been implicated in mediating various 
Postn-dependent effects, and macrophages in infiltrated sciatic nerves express both 
CD11b/ItgaM (Figure 3.13G) and ItgaV (Figure 3.18E). Inclusion of blocking antibodies 
specific to CD11b/ItgaM or ItgaV in the upper chamber of the transwell prevented RAW 
cells and NOD.AireGW/+ bone marrow-derived macrophages from migrating across the 
membrane, whereas IgG isotype control antibodies did not (Figure 3.18F,G). These 
data demonstrate that Postn is directly chemotactic to macrophages but not T cells, and 
that this response requires ItgaV and ItgaM.  
3.2.5 Macrophages promote the development of PNS autoimmunity.  
 
 While macrophages are a predominant cell type in the immune cell infiltrate of 
neuropathic nerves, their role in the development of autoimmune peripheral neuropathy 
in unclear. To address this, we first assessed expression of M1 and M2-associated 
markers. Macrophages were isolated from the sciatic nerve of neuropathic 
NOD.AireGW/+ mice and the expression of M1- and M2-associated markers was 
measured by qPCR. Since NOD.WT sciatic nerves have few resident macrophages, 
whole NOD.WT nerve tissue was used as a comparison. No significant difference was 
observed in the expression of M1-associated markers IL-12, iNos, or CD86 or M2-
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associated markers IL-10, Fizz, Mrc, or YM1 (Figure 3.19); however, a significant 
increase in the M1-associated markers CXCL9, CXCL10, and TNF and the M2-
associated markers Arg and TGFb was observed (Figure 3.20A-E). Additionally, the 
activation markers CD80, CD86, and MHCII were measured on nerve-infiltrating 
CD11b+ F4/80+ macrophages from sciatic nerves of neuropathic NOD.AireGW/+ mice by 
flow cytometry. Compared to CD11b- F4/80- non-macrophage cells, CD11b+ F4/80+ 
macrophages expressed more CD80, CD86, and MHCII (Figure 3.20F-H). CD11b- 
F4/80- non-macrophage cells from sciatic nerve of NOD.AireGW/+ expressed an 
intermediate amount of MHCII (Figure 3.20H), which may reflect upregulation of MHCII 
expression by other cell types such as Schwann cells (142-144). These data suggest 
that nerve-infiltrating macrophages are heterogeneous, expressing both M1- and M2-
associated markers, and express markers of activation.  
 Since nerve-infiltrating macrophages express both M1- and M2-associated 
markers, we wondered if Postn attracts macrophages of a specific phenotype. Postn 
has been suggested to recruit M2 anti-inflammatory macrophages (91), but whether 
Postn also recruits the M1 macrophage subtype is unclear. To test this, macrophages 
were skewed toward an M1 or M2 phenotype prior to inclusion in a transwell migration 
assay. Unskewed, M1-, and M2-skewed macrophages all migrated in response to Postn 
to a similar degree (Figure 3.20I) indicating that Postn is a chemotactic factor for both 
M1 and M2 macrophages. It has also been reported that Postn can regulate the 
expression of markers of M1 and M2 polarization (91). To determine whether Postn 
alters macrophage polarization, we skewed macrophages toward an M1 or M2 
phenotype in the presence or absence of Postn and measured the expression of M1 
50 
 
and M2 markers by qPCR. Postn did not change the expression of the M1-associated 
markers TNF and iNos or the M2-associated marker Arg (Figure 3.21). Thus, Postn 
does not impact macrophage polarization in vitro.     
Next, to determine whether macrophages contribute to SAPP, we treated 
NOD.AireGW/+ mice between 7 and14 weeks of age with clodronate liposomes to deplete 
phagocytic cells. Uptake of clodronate liposomes by phagocytes induces their 
apoptosis, and clodronate liposomes have previously been used to deplete 
macrophages in autoimmune mouse models (36, 145-147).  As expected, fewer F4/80+ 
CD11b+ macrophages were noted in the spleens of mice at 3 days after treatment with 
clodronate compared to vehicle control liposomes (Figure 3.22). Clodronate treatment 
was associated with a significant delay in the onset of peripheral neuropathy in 
NOD.AireGW/+ mice compared to vehicle liposome treatment (Figure 3.23A). Flow 
cytometric analysis of sciatic nerves of 21-week-old NOD.AireGW/+ mice demonstrated 
decreased frequency and absolute numbers of CD11b+ F4/80+ macrophages in the 
sciatic nerves of clodronate liposome-treated mice. Thus, clodronate treatment protects 
from SAPP through macrophage depletion (Figure 3.23B-C). In parallel, we investigated 
whether macrophage depletion was similarly protective in the AT model of inflammatory 
neuropathy. Clodronate or vehicle liposomes were administered to reconstituted 
NOD.SCID recipients from 5 weeks post transfer until mice developed neuropathy or 
were used in further experiments. Onset of clinical neuropathy in reconstituted 
recipients was significantly delayed with clodronate compared to vehicle liposome 
treatment (Figure 3.20J). Moreover, nerve conductions performed 5 weeks after 
administering clodronate (10 weeks after administering splenocytes) (Figure 3.20K-N) 
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showed increased CMAP peak amplitude (Figure 3.20L), decreased CMAP duration 
(Figure 3.20M), and faster nerve conduction velocity (Figure 3.20N) with clodronate 
treatment. Thus, in the AT model, clodronate-mediated depletion of macrophages 
protects against the development of demyelinating neuropathy, which suggests a 
pathogenic role for macrophages in inflammatory neuropathy.  
3.2.6 TNFα 
 
 Neuropathic NOD.AireGW/+ mice express increased TNFα mRNA compared to 
NOD.Aire+/+ non-neuropathic mice (Figure 3.24A). Phenotypic analysis of nerve-
infiltrating macrophages revealed that high levels of the cytokine TNFα (Figure 3.24B). 
TNFα is a pleiotropic cytokine that may induce apoptosis through TNF receptor (TNFR) 
1 or cell proliferation through TNFR2 (148). To determine whether TNFα is pathogenic 
during SAPP and whether TNFα signals through TNFR1 or TNFR2 during neuropathy, 
we crossed NOD.AireGW/+ mice to TNFR deficient mice and tracked the development of 
neuropathy. TNFR1/ TNFR2 double deficient mice were completely protected from 
SAPP. Furthermore, TNFR1 deficiency prevented the development of SAPP, but 
TNFR2 deficiency did not (Figure 3.24C). Thus, TNFα is pathogenic during SAPP and 
signals through TNFR1. 
Postn has been reported to regulate TNFα expression (81, 90), and TNFα was 
expressed primarily by macrophages in SAPP (Figure 3.24A); therefore, we 
hypothesized that in addition to promoting macrophage chemotaxis, Postn regulates 
TNFα expression in macrophages. To test this hypothesis, we measured the TNFα 
concentration in supernatant of macrophages cultured in the presence of Postn by 
enzyme-linked immunosorbent assay (ELISA). While RAW cells increased TNFα 
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expression in response to Postn (Figure 3.24D), bone-marrow derived (Figure 3.24E) 
and peritoneal macrophages (Figure 3.24F) did not. The increased TNFα in RAW cells 
exposed to Postn is likely an artifact since primary macrophages failed to respond to 
Postn. 
3.3 Discussion 
 
 The development of tissue-specific autoimmunity involves a complex interplay 
between autoreactive immune cells and the target tissue. Whether the PNS regulates 
disease progression in autoimmune neuropathies, however, has not been documented. 
We show here that Schwann cells participate in the immune response by upregulating 
the extracellular matrix protein Postn. Postn expression was increased in multiple 
mouse models of CIDP, suggesting that this may be a generalizable finding in 
inflammatory neuropathies. The absence of Postn delayed the disease onset and 
reduced the severity of neuropathy. Postn deficiency also resulted in improved nerve 
function by EMG and reduced immune cell infiltration into nerves. Together, these 
findings suggest that Schwann cell-derived Postn promotes PNS autoimmunity by 
enhancing immune cell infiltration (Figure 5.2). 
Postn is upregulated in various diseases (149) including cancer (78), myocardial 
infarction (79), asthma (80), skin inflammation (81), glomerulonephritis (82), and colitis 
(83). TGFb or neuregulin/ErbB3 signaling  (77, 85) can induce Postn expression in 
Schwann cells during development; additionally, Postn expression can also be induced 
by IL-4 and IL-13 in keratinocytes during allergic skin inflammation (81) and by TNFa 
and IL-17 during liver fibrosis (84). Postn signals through ItgaVb3 (81, 87), ItgaVb5 (87), 
and ItgaM (eosinophils) (88) and results in the phosphorylation of focal adhesion kinase 
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(FAK) (89) and AKT (89) in neurons and the activation of NF-kB (81, 83) in 
keratinocytes and colon. Postn regulates various cytokines and chemokines including 
TNFa  in skin inflammation and following spinal cord injury (81, 90); IL-1a, GM-CSF, 
and chemokine ligand CCL17 in allergic skin inflammation and glioblastoma (81, 91); 
RANTES (CCL5) in kidney and nasal epithelia (82, 93); and CCL2, CCL4, CCL7, and 
CXCL2 in pulmonary fibrosis (92). Additionally, Postn has been shown to promote 
immune cell recruitment to sites of inflammation in spinal cord injury and glioblastoma 
(90-92) . We saw a similar effect of Postn on recruitment of immune cells to the sciatic 
nerves during SAPP.  
While both T cell and macrophage numbers were reduced in peripheral nerve of 
Postn-deficient mice, only macrophages responded to Postn in an in vitro transwell 
migration assay. This finding suggests that Postn primarily promotes macrophage 
chemotaxis, and does not directly promote T cell chemotaxis. Instead, Postn may 
promote T cell influx indirectly through recruitment of macrophages that in turn express 
T cell chemoattractants. This notion is consistent with our observation (Figure 3.20A, B) 
that nerve-infiltrating macrophages express the T cell chemoattractants CXCL9 and 
CXCl10. Additionally, Postn has been reported to regulate other T cell chemoattractants 
including RANTES (82, 93), which is secreted by macrophages during EAN (116), and 
chemokine ligand CCL17 (81). Thus, we propose a positive feedback loop between T 
cells and macrophages. This cycle is likely initiated by PNS-specific CD4+ T cells, given 
our data that CD4+ T cells are sufficient to incite SAPP in immunodeficient mice (24). 
These early infiltrating T cells produce TGFb, which induces Schwann cells to express 
Postn. By binding to ItgaM and ItgaV on macrophages, Postn attracts macrophages into 
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the endoneurium. This amplifies a positive feedback loop between macrophages and T 
cells through increased macrophage expression of T cell chemoattractants CXCL9 and 
10 (Figure 5.2).  
In mouse and rat models of nerve injury, macrophages are recruited 3-5 days 
after injury (150). In this setting, macrophages are important in clearing myelin debris 
and participate in nerve regeneration by secreting growth-promoting factors and 
cytokines that act upon Schwann cells and neurites (32). Given this reparative role for 
macrophages during axotomy, Postn’s promotion of macrophage infiltration may have 
both pro-inflammatory and reparative effects. Further, it is also possible that Postn-
dependent macrophage infiltration may even be anti-inflammatory since nerve-
infiltrating macrophages express some immunosuppressive M2-associated markers, 
and data from our group and others show that Postn can promote M2 macrophage 
chemotaxis (91). Our results indicate that macrophages overall were pro-inflammatory 
during PNS autoimmunity since macrophage depletion delayed the onset of disease. 
Nevertheless, it is important to acknowledge that the macrophage population is likely to 
be heterogeneous (151), given that both M1- and M2-associated markers were 
expressed (Figure 3.20A-E), and a subset of PNS-infiltrating macrophages may 
ameliorate disease. Further delineation of macrophage subsets and their function in 
SAPP will be the subject of future studies. 
In addition to SAPP and axotomy, other disease states are also associated with 
macrophage infiltration in the PNS, including some hereditary neuropathies (152). At 
present, it is not clear whether the same chemotactic factors mediate macrophage influx 
in each of these conditions. Multiple factors, such as CCR2/CCL2 interactions, have 
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been implicated in macrophage recruitment after nerve injury (153). CCR2 is expressed 
on infiltrating macrophages, and CCL2 (also known as MCP) secretion by Schwann 
cells recruits macrophages into the injured nerve (154-156). Additionally, MIP-1a and IL-
1b also play important roles in macrophage chemotaxis with axotomy (154). Whether 
Postn also plays a role in macrophage infiltration with hereditary neuropathies, and 
whether CCR2/CCL2, MIP-1a, and IL-1b might promote macrophage infiltration during 
autoimmune peripheral neuropathy, awaits further investigation. 
 In the central nervous system (CNS), Postn is expressed by several glial cell 
types including astrocytes (89) and pericytes (90) following injury. Postn promotes scar 
formation, regulates blood brain barrier permeability, and induces proinflammatory 
molecules such as MMP9 leading to impaired functional recovery following spinal cord 
injury (90) and increased pathology following subarachnoid hemorrhage (157). In 
contrast to the CNS, we did not observe increased Postn expression following PNS 
injury. The regenerative capacity of the PNS is markedly better than that of the CNS; 
however, the underlying reasons for this difference in regenerative capacity are poorly 
understood. Since Postn deficiency improves recovery following CNS injury, we 
speculate that lack of Postn upregulation following PNS injury may partially account for 
the improved ability of the PNS to repair itself.  
 In preclinical trials, Postn inhibitors have shown promise as cancer therapeutics 
and both antibody-based and aptamer Postn inhibitors are actively being pursued (158, 
159). Our finding that Postn is induced in mouse models of inflammatory neuropathy 
and required for macrophage-mediated disease acceleration suggests that Postn 
inhibition may be a potential immunotherapeutic strategy for inflammatory neuropathies. 
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Since Postn recruits macrophages to the PNS through interaction with ItgaV, targeting 
ItgaV is another potential strategy implicated by our results. Currently, several antibody 
and small molecule inhibitors of ItgaV are in phase I and phase II clinical trials for 
treatment of cancer (160, 161). Our results provide a basis for the development of these 
molecules as novel therapeutics for inflammatory neuropathies. 
3.4 Methods 
 
3.4.1 Animals 
 
 Strains and housing. Mice were housed in a specific pathogen-free facility at the 
University of North Carolina at Chapel Hill (UNC-CH). NOD.AireGW/+ and myelin protein 
zero T cell receptor transgenic (NOD.P0T) mice were generated as previously 
described (25, 30). NOD.POT Tcr Tg mice were a kind gift from Jeffrey Bluestone 
(University of California at San Francisco). NOD.SCID mice were purchased from the 
Jackson Laboratory. B6.PostnlacZ/+ mice (136) were purchased from the Jackson 
Laboratory and were backcrossed onto the non-obese diabetic (NOD) background for 8 
generations using speed congenics (25). Genome scanning to select breeders of 
highest NOD strain origin was performed by JAX services using a 150 SNP panel that 
was polymorphic between NOD and C57BL/6. NOD. PostnlacZ/+ were then crossed to 
NOD.SCID mice to generate NOD.PostnlacZ/+ SCID and NOD.PostnlacZ/lacZ SCID (also 
referred to as NOD.Postn-/- SCID) mice.  
 Adoptive transfer (AT) model: 48-well plates were coated with anti-CD3 
(eBioscience clone 145-2C11; 1 µg/ml in PBS) and anti-CD28 (BD Pharmingen clone 
37.51; 1 µg/ml in PBS) overnight at 4°C or for at least 2 hrs at 37°C and washed with 
PBS. Splenocytes from neuropathic NOD.AireGW/+ or NOD.P0T mice were plated at a 
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density of 106 (NOD.AireGW/+) or 5 x 105 (P0T) cells/well and were cultured for 96-120 
hrs in DMEM supplemented with 10% fetal bovine serum, 10 mM HEPES buffer 
(NOD.P0T mice only), penicillin-streptomycin (100 U/mL, Gibco), and 2-
mercaptoethanol (55 µM). 1X106 activated splenocytes were harvested, washed once 
with sterile PBS, and adoptively transferred in sterile PBS using retro-orbital injection 
into immunodeficient NOD.SCID recipients sedated with 2% isoflurane in oxygen. 
 Evaluation of SAPP: Mice were evaluated weekly (spontaneous model) or every 
other day (AT model) for clinical signs of neuropathy, which was scored as follows: 0-no 
signs of neuropathy present, 1-mild hind limb weakness, 2-pronounced bilateral hind 
limb weakness, 3-reduced or absent ability to grip cage grating, 4-moribund. For 
neuropathy incidence curve, mice were considered neuropathic when they reached a 
score of 2 in order to limit the effect of false positives. SAPP was confirmed by 
electromyography, which was performed as previously described (27, 110). 
 Surgery: Mice were anesthetized with isoflurane and 100 mg/kg ketamine/10 
mg/kg xylazine or 250 mg/kg avertin. Fur was removed from the surgical area with 
depilatory cream and cleaned with alcohol wipes. The sciatic nerve was exposed and 
transected at the sciatic notch. The contralateral nerve was exposed, but left intact 
(mock). The wound was sealed with surgical glue. 10 mg/kg meloxicam was 
administered at the time of surgery, and 2 mg/kg meloxicam was administered daily 
following surgery for pain management. 3 days following nerve transection surgery, 
nerves were harvested, frozen in liquid nitrogen, and stored at -80°C until use. RNA was 
extracted from transected and mock nerves and Postn was measured by qPCR. 
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3.4.2 Flow Cytometry 
 
 Nerve digestion: Nerves were chopped into segments with a razor blade and 
digested in PBS containing 1 mg/ml collagenase and 1% FBS at 37°C for 30 min with 
periodic agitation. Part-way through the digestion, the sample was triturated with a 20g 
needle to aid in tissue disruption. Dissociated nerves were filtered through 40 µm mesh 
and washed prior to use in experiments.   
 Antibodies: CD3 (Clone 145-2C11), CD4 (Clone RM4-5), CD8 (clone 53-6.7), 
F4/80 (Clone BM8), and CD45 (Clone 30F11) antibodies were purchased from 
eBioscience. CD11b (Clone M1/70) was purchased from BioLegend. Live/dead fixable 
yellow dye (Life Technologies) was used to exclude dead cells. rabbit anti-P75 (Abcam; 
1:500) DyLight 488-conjugated goat anti-rabbit IgG (Thermo Fisher; 1:500) 
 Staining. Single cell suspensions were washed twice with FACS buffer. Fc 
receptors were blocked by incubating cells with supernatant from a 2.4G2 hybridoma for 
10 min. Cells were stained for 30 min on ice and washed prior to analysis. 
Analysis: Samples were run on Beckman Coulter CyAn ADP or Becton Dickinson LSRII 
flow cytometers and analyzed using FlowJo software. A Becton Dickinson FACSAriaII 
was used for sorted samples. 
3.4.3 Immunostaining 
 
 Mouse: Nerves from NOD.AireGW/+ and NOD.WT mice were embedded in OCT 
and frozen at -20°C for 2 hrs prior to storage at -80°C. 6 µm sciatic nerve cross-sections 
or longitudinal sections were fixed with cold acetone, blocked with 2.5% goat serum, 
and stained with 10 µg/ml anti-periostin (Abcam), F4/80 (ebisocience) and CD3 
(BioLegend) for 2 hrs. After washing with PBS containing 0.1% Tween (PBST), sections 
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were incubated with anti-rat-HRP or anti-rabbit-HRP (VECTOR Laboratories) antibody 
for 30 mins, and developed in diaminobenzidine (DAB) solution until desired stain 
intensity was achieved. All sections were processed in parallel, including the same 
length of time in the DAB solution. Samples were imaged on a Nikon Eclipse 80i 
widefield microscope. 
 Human: Slide-mounted cryosections of sciatic nerves from deidentified CIDP 
patients were air dried and fixed with 2% paraformaldehyde (PFA), washed in 
phosphate buffered saline (PBS) and permeabilized with 0.2% Triton X-100. After 
blocking with 5% goat serum, sections were washed in PBS, and incubated with 1:50 
rabbit polyclonal anti-human periostin (Abcam, catalogue number ab14041) and 1:200 
mouse monoclonal anti-human S-100 β (Atlas, catalogue number AMAb91038, Clone 
CL2720) for 18 hr at 4°C.  Sections were washed with PBS and incubated with 1:200 
Alexafluor 594 labeled goat polyclonal anti-rabbit secondary antibody (Invitrogen, 
catalogue number A11037) and 1:200 Alexafluor 488 labeled goat polyclonal anti-
mouse secondary antibody (Invitrogen, catalogue number A11001) at room temperature 
for 1 hr. After incubation with secondary antibody, slides were washed with PBS and 
coverslipped using antifade medium containing 4′,6-diamidino-2-phenylindole (Prolong 
Gold; Invitrogen, catalogue number P36931) and photographed using a Zeiss 800 
Confocal microscope. 
3.4.4 Transwell migration assay  
 
 T cells: Chemotaxis was measured using transwell assays as described by (162). 
Migration of CD4+ T cells was measured using a 24-well transwell plate (Corning Life 
Sciences) with 6.5 mm polycarbonate filters and 5 µm pores. CD4+ T cells from 
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neuropathic NOD.AireGW/+ spleens were purified using the Magnisort CD4+ T cell 
Enrichment Kit (Invitrogen). Two million CD4+ T cells were resuspended in transwell 
media (100 µl RPMI 1640 medium with 0.1% fatty acid-free BSA (Sigma-Aldrich), 100 
U/ml penicillin G, 2 mM L-glutamine, and 25 mM HEPES buffer). Cells were placed on 
the transwell inserts. Six hundred microliters of media, media + PBS, or media + 50-
1000 ng/mL Postn (R&D Systems) were added to the lower chambers. Migration was 
performed for 4 hrs at 37 ºC and 5% CO2. Migrated cells were counted with a 
hemocytometer. 
 Macrophages: Bone marrow was flushed out of the femur and tibia of 
NOD.AireGW/+ mice using PBS and cultured in DMEM containing 10% FBS, P/S, and 
10% L cell supernatant for 5 days prior to use. RAW 264.7 cells or NOD.AireGW/+ bone-
marrow derived macrophages were cultured in DMEM with 10% FBS in a 24-well plate. 
Cells were washed three times with PBS, re-suspended in DMEM without FBS, and 
seeded at 1X106 cells/ml into the upper chamber in a total volume of 250 µl. Transwell 
inserts with 8 µm pores (Corning) were used. Recombinant Postn (R&D Systems) was 
added to the lower chamber at 50, 100, 200, 500 and 1000 ng/ml in DMEM with 5% 
FBS. Anti-CD11b (Thermo Fisher) and anti-CD51 (ItgaV) (BD) were added into the 
upper chamber at a concentration of 10 µg/ml. For experiments comparing M1 and M2 
macrophages, 200,000 bone marrow-derived macrophages were seeded in the upper 
chamber of the transwell in a total volume of 350µl. Macrophages were incubated with 
or without macrophage skewing conditions for 24 hr, then the upper chamber was 
changed to serum-free DMEM culture medium, and the lower chamber was changed to 
DMEM with 5% FBS with or without 100 ng/ml POSTN. Cells were allowed to migrate 
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through the transwell insert membrane for 24 hr. The inserts were removed, fixed in 
cold methanol, and stained with methanol containing 1% crystal violet. The inside of the 
transwell was swabbed thoroughly with cotton swabs and air-dried at room temperature 
overnight. The number of migrated raw cells and macrophages was counted by bright 
field microscopy at 40X. Four bright field images were analyzed per well. Values from 
each well were averaged and normalized to the media control. At least 3 mice were 
used per condition over at least 2 separate experiments.  
3.4.5 Macrophage skewing 
 
 Bone marrow-derived macrophages were seeded at 250,000 cells/well in 24-well 
plates in DMEM medium containing 10% FBS and 1% P/S. 100 ng/ml LPS and 25 ng/ml 
IFNg were added to the media for M1 differentiation, and 25ng/ml IL-4 was added to the 
media for M2 differentiation. After 24 hr in skewing conditions, 100 ng/ml Postn was 
added to some of the cultures and the macrophages were cultured for another 24 hr. 
Total RNA was extracted from the macrophages and used in quantitative RT-PCR 
analyses. CXCL9, CXCL10, CD86, iNOS, IL-12 and TNF were used as M1 markers, 
and IL-10, YM1, Arg1, Fizz, and Mrc were used as M2 markers. 
3.4.6 Human Schwann Cell culture and stimulation 
 
 Immortalized human Schwann cells (HSC) were cultured as described (163). 
HSC were grown to 80% confluence and seeded into 12-well plates at a density of 
250,000 cells in 2 mL growth media per well. After 24 hr at 37°C in a humidified 5% 
CO2 incubator, serum free media was used and cells were treated with 1 ng/ml TGFb 
(StemCell), 10 ng/ml NRG1 (Thermo Fisher), or both for 24hr at 37°C with 5% CO2. 
Postn expression was measured by qPCR.  
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3.4.7 Macrophage Depletion 
 
 AT model.  Mice were treated with 200 µl of clodronate or vehicle control 
liposomes 5 weeks post AT. Each following week mice received 100µl of clodronate or 
control liposomes until neuropathy developed. AireGW/+ spontaneous model. Mice were 
treated weekly for 7 weeks with 200 µl of clodronate or vehicle control liposomes 
starting at 7 weeks of age. Treatment was discontinued after 7 weeks of treatment due 
to the development of ascites. Clodronate and control liposomes were purchased from 
Encapsula NanoSciences LLC. 
3.4.8 X-gal Staining of Sciatic Nerves and electron microscopy 
 
 Mice were euthanized and perfused with 0.1M phosphate buffer (PB) followed by 
cold 0.5% glutaraldehyde (Sigma-Aldrich) in 0.1M PB. Sciatic nerves were fixed in 0.5% 
glutaraldehyde in 0.1M PB for 3 hrs at 4°C. Nerves were washed twice with 0.1M PB 
then twice with 2 MgCl2 in 0.1M PB. Samples were incubated overnight at 37°C in X-gal 
working solution: 2.0 mM MgCl2 (Sigma-Aldrich), 4.0 mM K4Fe(CN)6 (Sigma-Aldrich), 
4.0 mM K3Fe(CN)6 (Sigma-Aldrich), and 1.0 mg/mL X-Gal (5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside, Sigma-Aldrich) in 0.1M PB. Nerves were washed twice in 0.1M 
PB, post-fixed in 4% glutaraldehyde (Sigma-Aldrich) overnight at 4°C, rinsed in 0.1M 
PB, transferred to a 2% OsO4 in 0.1M PB for 1 hr, then processed for embedding in 
Epon. Semi-thin sections were stained with 1% paraphenylenediamine or alkaline 
toluidine blue, and visualized by light microscopy (Leica DMR) using interactive 
software (Leica Application Suite). Thin sections were stained with lead citrate and 
imaged in a Jeol-1010 transmission electron microscope. Selected images were 
processed with Photoshop to generate the figures. 
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3.4.9 Quantitation of demyelination 
 
 Semi-thin sections of tibial nerve stained with 1% paraphenylenediamine were 
analyzed using Fiji software. The area of each tibial nerve was determined based on the 
inner edge of the perineurium The total number of myelinated axons in each cross 
section was counted manually using Fiji to mark each myelinated axon. The following 
formula was used to determine the number of myelinated axons per 1000 µm2: (number 
of total axons in the tibial nerve/total area of the tibial nerve) x 1000. 
3.4.10 qPCR 
 
 Primers: We used the following primers: Arg (Mm00475988_m1), CD86 
(Mm00444543_m1), Fizz (Mm00445109_m1), iNos (Mm00440502_m1), Mrc 
(Mm01329362_m1), Lama2 (Mm00550083_m1), Lama4 (Mm01193660_m1), Lama5 
(Mm01222029_m1), Lamb1 (Mm00801853_m1), mouse Postn (Mm01284919_m1), 
human Postn (Hs01566750_m1), Thbs2 (Mm01279240_m1), TNF (Mm00443258_m1), 
and YM1 (Mm00657889_mH). The primer probe set for Cyclophilin A (27) or GAPDH 
(Hs02758991_g1) were used as internal controls. 
 Whole sciatic nerves were homogenized by mortar and pestle followed by 
QIAshredder. RNA was isolated from whole nerve using Qiagen RNeasy Plus Mini kit or 
Zymo RNA MicroPrep kit. Agilent Absolutely RNA Nanoprep Kit was used to isolate 
RNA for samples with fewer than 104 cells. Qiagen RNeasy Plus Micro Kit was used for 
samples with between 104 and 5x105 cells. SuperScript II (Invitrogen) reverse 
transcriptase was used for cDNA synthesis. TaqMan Universal PCR Master Mix 
(Applied Biosystems) was used for PCR. The Applied Biosystems QuantStudio 6 Flex 
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Real Time PCR System and Quantstudio 6-7 software were used for data acquisition 
and analysis respectively.  
3.4.11 Western Blot 
 
 Whole sciatic nerves were homogenized in Laemmle buffer. Proteins were 
separated by SDS-PAGE and Novex NUPAGE 4-12% Bis-Tris gel (Life Technologies) 
and transferred to methanol-activated PVDF membranes (Thermo Scientific). The blot 
was blocked with 5% nonfat dry milk in Tris-buffered saline (TBS) for 1 hr at room 
temperature and subsequently incubated overnight at 4°C with polyclonal anti-periostin 
(Abcam) diluted to 1:5000 in TBS with 0.01% Tween-20 (TBST) and 5% nonfat dry milk. 
Blots were washed, incubated with 1:10,000 HRP-conjugated goat anti-rabbit (Abcam) 
in blocking buffer for 1 hr at room temperature, and washed again. Blots were 
developed by SuperSignal™ West Femto Maximum Sensitivity Substrate and exposed 
to X-ray film. GAPDH was used as a loading control. After three washes for 10 min with 
TBST and one wash for 5 min in TBS, the blot was incubated with HRP conjugated 
mouse anti GAPDH (Thermo scientific) diluted to 1:1000 for 1 hr at room temperature. 
The blot was washed and developed by SuperSignal™ West Femto Maximum 
Sensitivity Substrate and exposed to X-ray film or imaged with a BioRad Chemidoc. 
3.4.12 Statistics 
 
Statistics were performed with GraphPad Prism software or R. For neuropathy 
incidence curves the log-rank (Mantel-Cox) test was used. Unpaired two-tailed T-tests 
were used when comparing 2 groups with continuous values. Welch’s correction was 
applied when the standard deviation was different for each group. For discrete data, 
Fisher’s exact test was performed in R.  ANOVA with multiple comparisons was used 
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when comparing 3 or more groups. A paired T-test was used when samples in the 
experimental group were obtained from the same animal as the control group as in the 
nerve transection surgery. For the macrophage chemotaxis assay, statistics were 
performed in R using the lm() function where parameters were fit to each mouse as well 
as the difference in treatment. p-values were calculated by comparing the fit of the full 
model to a model without a term for the difference in treatment. p-values were adjusted 
using the Bonferroni correction. p<0.05 was considered significant. 
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 All animal experiments were performed in compliance with the Animal Welfare 
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Figure 3. 1: Increased Postn expression in SAPP. A-F) RNA was isolated from the 
sciatic nerves of NOD.WT (WT) and NOD.AireGW/+ neuropathic mice. Laminin a2 
(Lama2, A), laminin a4 (Lama4, B), laminin a5 (Lama5, C), laminin b1 (Lamb1, D), 
thrombospondin (Thbs, E), and periostin (Postn, F) expression relative to cyclophilin 
was measured by qPCR. Values are expressed as fold change compared to WT.   
G) Postn expression was measured by Western blot from sciatic nerve lysates from 
NOD.WT (WT) and NOD.AireGW/+ neuropathic mice. Gapdh was used as a loading 
control. Each lane represents an individual mouse. H) Densitometric analysis of 
Western blot in F. I) Postn immunohistochemical staining of sciatic nerve from WT, 
neuropathic NOD.AireGW/+, neuropathic SCID recipients of NOD.AireGW/+ splenocytes, 
and neuropathic SCID recipients of P0T splenocytes. Note Postn-immunoreactivity is 
mostly found in the perineurium (arrowheads) of NOD.WT (WT) nerves, whereas the 
endoneurium is diffusively positive in nerves from NOD.AireGW/+, SCID. NOD.AireGW/+ 
AT (AT: adoptive transfer), and SCID.P0T AT mice. Scale bar is 180 µm.  
J) Immunofluorescent staining of biopsies from patients with axonal neuropathy or 
CIDP; there is increased endoneurial Postn-immunoreactivity in the CIDP sample. Scale 
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bar is 200 µm.  Each dot represents an individual animal.  *p<0.05, **p<0.005, 
****p<0.0001 by two-tailed, unpaired T test.  
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Figure 3. 2: Postn is upregulated in neuropathic compared to pre-neuropathic 
NOD.AireGW/+ mice. Postn expression in NOD.WT mice, Postn-/- mice and NOD.AireGW/+ 
mice at different ages. Postn expression was measured by qPCR in 20-week-old 
NOD.WT, 20-week-old B6.Postn-/-, 8-week-old (pre-neuropathic) NOD.AireGW/+, and 20-
week-old NOD.AireGW/+ mice. Values are represented as fold change over NOD.WT. 
Each dot represents an individual animal. **p<0.005 by ordinary one-way ANOVA with 
Tukey’s test for multiple comparisons.  
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Figure 3. 3: Postn protein is absent in NOD.Postn-/- mice. Postn expression was 
measured by Western blot from sciatic nerve lysates from NOD.AireGW/+ neuropathic, 
NOD.WT (WT), and NOD.Postn-/- mice. Gapdh was used as a loading control. Each 
lane represents an individual mouse.  
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Figure 3. 4: Postn expression is unaltered following nerve transection. The sciatic 
nerve of B6 mice was transected (cut) or exposed but left intact (mock). Three days 
following nerve transection surgery, RNA was isolated from sciatic nerve and Postn was 
measured by qPCR. Each dot represents an individual mouse. Lines connect mock and 
cut samples from the same mouse. p=0.32 by paired T test. 
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Figure 3. 5: Postn is expressed by Schwann cells. Histochemistry for beta-
galactosidase using X-gal was performed on sciatic nerves from NOD.WT Postnlacz/+ 
(WT, n=4) and NOD.AireGW/+ PostnlacZ/+ (top, n=3) as well as NOD.SCID.PostnlacZ/+ 
reporter mice without (n=4) or with (n=8) adoptive transfer (AT) with NOD.AireGW/+ 
splenocytes (bottom). A) Macroscopic view of sciatic nerve cross sections. The 
perineurium of WT and NOD.SCID.PostnlacZ/+ nerves is X-gal-positive (arrowhead); the 
endoneurium (E) is also X-gal-positive in NOD.AireGW/+ PostnlacZ/+ and 
NOD.SCID.PostnlacZ/+ that had AT. Original magnification is 4.5x. B) Semi-thin sections 
(stained with paraphenylenediamine). X-gal crystals are blue, some large clusters are 
indicated (arrowheads) in a region with reduced density of myelinated axons. Original 
magnification is 100x. C-E) Electron microscopy. Arrowheads indicate X-gal crystals, 
which are electron-dense. * indicates axons. X-gal crystals are found in promyelinating 
(C), non-myelinating (D), and myelinating (E) Schwann cells. Scale bars are 2 µm (C, E) 
or 500 nm (D). F) Postn expression relative to cyclophilin measured by qPCR. RNA was 
isolated from whole sciatic nerve of NOD.WT mice, CD11b+ or CD3+ cells enriched 
from NOD.AireGW/+ neuropathic mice, or p75+ Schwann cells purified from sciatic nerves 
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of WT and affected NOD.AireGW/+ neuropathic mice. Each dot represents an individual 
mouse. G) Immunofluorescent staining of S100b (green) and Postn (red) in CIDP 
patient biopsies. Scale bar is 20 µm. H) Human Schwann cells (HSC) were cultured with 
neuregulin 1 (NRG1), TGFb, or both NRG1 and TGFb. Postn expression was measured 
by qPCR. Each dot represents an individual well. **p<0.005, ***p<0.0005 by one-way 
ANOVA with multiple comparisons. 
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Figure 3. 6: Periostin is expressed by non-Schwann cells. Histochemistry for beta-
galactosidase using X-gal was performed on sciatic nerves from NOD.SCID.PostnlacZ/+ 
reporter mice with adoptive transfer (AT) of NOD.AireGW/+ splenocytes and nerves were 
imaged with electron microscopy. Arrowheads indicate X-gal crystals, which are 
electron-dense. * indicates axons. The dotted line indicates a cell outline. X-gal crystals 
are found in the nuclear membrane of cells that lack a basal lamina (A, B), and cells that 
have crossed the Schwann cell basal lamina but do not associate with an axon (C). 
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Figure 3. 7: X-gal crystals are specific to the lacZ transgene. Semi-thin section 
(stained with paraphenylenediamine) of a NOD.SCID.Postn+/+ adoptively transferred 
with NOD.AireGW/+ splenocytes. X-gal crystals are absent.  
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Figure 3. 8: Gating strategy for isolation of p75+ Schwann cells from SAPP mice. 
A) Diagram of the gating strategy used to isolate live, CD45- p75+ Schwann cells from 
sciatic nerve of neuropathic NOD.AireGW/+ mice. First, debris was excluded by drawing a 
large gate on forward scatter (FSC) area (A) versus side scatter (SSC)-A labelled 
“Cells”. Next doublets were excluded by drawing a gate around singlets on SSC height 
(H) versus width (W) followed by drawing a gate around singlets on FSC height versus 
width. Next, dead cells were excluded and CD45 was used to distinguish hematopoietic 
cells from nerve-resident cells. Within the CD45- gate, p75+ cells were identified using 
an “unstained” control in which the sample included all dyes and antibodies in the stain 
set except anti-p75. Within the CD45+ gate, CD3+ T cells were identified and collected 
for use as a negative control for Postn expression. B) Representative plot showing the 
CD3 post-sort purity. The plot was pregated on CD45+ events as shown in A.  
C) Representative plot showing p75 post-sort purity. The plot was pregated on CD45- 
events as shown in A. numbers represent the average frequency and standard 
deviation of events within the gate. 
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Figure 3. 9: TGFb is highly expressed in sciatic nerves during SAPP. TGFb 
expression was measured in sciatic nerve of NOD.WT and NOD.AireGW/+ neuropathic 
mice by qPCR. Each dot represents an individual mouse. ****p<0.0001 by two-tailed T 
test.  
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Figure 3. 10: Postn deficient mice have normal peripheral nerves. A) Clinical 
evaluation of NOD.Postn+/- and NOD.Postn-/- mice. Normal mice will extend their hind 
limbs to the side when lifted by the tail, whereas neuropathic animals are unable to do 
so.  Representative CMAPs of NOD.Postn+/- and NOD.Postn-/- mice. NOD.Postn-/- and 
NOD.Postn+/- mice had similar CMAP peak amplitudes (C, p=0.99), CMAP durations (D, 
p=0.99), and conduction velocities (E, p=0.63). Each dot represents an individual 
animal. Light (F) and electron microscopy (G) of semi-thin and thin sections, 
respectively, revealed no abnormalities of NOD.Postn-/- sciatic nerves. F) Original 
magnification 100x. G) Scale bar is 2 µm. P-values were calculated using two-tailed, 
unpaired t tests. 
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Figure 3. 11: Postn deficiency protects against neuropathy. NOD.SCID.Postn+/+, 
NOD.SCID.Postn+/-, and NOD.SCID.Postn-/- mice after adoptive transfer (AT) with 
NOD.AireGW/+ activated splenocytes.  NOD.SCID.Postn-/- mice were compared to 
NOD.SCID.Postn+/+ or NOD.SCID.Postn+/- mice. A) Neuropathy incidence curve 
showing onset of clinical symptoms. Dotted line represents the time point when mice 
were used in experiments (10 wks post AT). B) Representative compound muscle 
action potential (CMAP) traces from 10 weeks post AT. The CMAP of the 
NOD.SCID.Postn+/- nerve had a smaller amplitude, and was more dispersed than that of 
the NOD.SCID.Postn-/- nerve (note difference in scale of y-axis; 2 vs 20 mV). C) Peak 
amplitude, D) conduction velocity, and E) duration of CMAPs from mice in A. Each dot 
represents an individual mouse. F) Representative images of semi-thin sections of 
sciatic nerve from NOD.SCID.Postn+/- (n=8) and NOD.SCID.Postn-/- (n=3) recipients of 
NOD.AireGW/+ activated splenocytes. Original magnification is 100x. G) The number of 
myelinated axons/1000 µm2 was counted in tibial nerve cross sections of 
NOD.SCID.Postn+/- and NOD.SCID.Postn-/- AT recipients. H) Electron microscopy. 
There are demyelinated axons (*) in the NOD.SCID.Postn+/- nerve (n=8), whereas the 
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NOD.SCID.Postn-/- (n=3) nerve looks normal. Scale bar is 2 µm. I) H&E staining of 
sciatic nerve. The NOD.SCID.Postn+/- nerve is heavily infiltrated by hematoxylin-positive 
nuclei compared to the NOD.SCID.Postn-/- nerve. Scale bar is 12 µm. J) Infiltration 
scores were assigned as follows: 0=no infiltration, 1=1-25% of the nerve is infiltrated, 
2=26-50% of the nerve is infiltrated, 3=51-75% of the nerve is infiltrated, 4= 76-100% of 
the nerve is infiltrated. Each dot represents an individual mouse. *p<0.05, **p<0.005 by 
log-rank test (A), two-tailed, unpaired T test with Welch’s correction (C-E, G), or Fisher’s 
exact test (J). 
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Figure 3. 12: NOD.SCID Postn+/+ and NOD.SCID Postn+/- mice develop neuropathy 
at the same incidence. Neuropathy incidence curve showing onset of disease in 
NOD.SCID Postn+/+ and NOD.SCID Postn+/- mice. p=0.95 by log-rank test. 
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Figure 3. 13: Postn-deficient mice have fewer infiltrating T cells and 
macrophages. Flow cytometry was used to evaluate the immune cell infiltrate of sciatic 
nerves of NOD.SCID.Postn+/+, NOD.SCID.Postn+/-, and NOD.SCID.Postn-/- mice 10 
weeks after adoptive transfer (AT) with NOD.AireGW/+ activated splenocytes. A) 
Representative histograms of CD45 staining. B) Frequency and C) total number of 
CD45+ cells. D) Representative dot plots of CD3 versus live/dead staining. E) 
Frequency and F) total number of CD3+ cells. G) Representative flow plots of F4/80 
versus CD11b staining. H) Frequency and I) total number of F4/80, CD11b double-
positive cells. Each dot represents an individual mouse. *p<0.05, **p<0.005, 
***p<0.0005, ****p<0.0001 by two-tailed, unpaired t test with Welch’s correction. 
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Figure 3. 14: T cells and macrophages infiltrate the sciatic nerve of adoptively 
transferred mice. A) CD3, and B) F4/80 immunohistochemical staining of sciatic nerve 
from NOD.SCID mice without and with AT of NOD.AireGW/+ splenocytes. Mice with and 
without AT were processed in parallel.   
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Figure 3. 15: T cell and macrophage numbers are similar in NOD.Postn+/+ and 
NOD.Postn-/- mice. A) Representative dot plots showing CD3 versus CD11b staining 
on splenocytes from NOD.Postn+/+ and NOD.Postn-/- mice. Frequency (B, D) and total 
numbers (C, E) of CD3+ T cells (B, C) and CD11b+ macrophages (D, E).  
F) Representative dot plots showing CD8 versus CD4 staining of NOD.Postn+/+ and 
NOD.Postn-/- mice. Frequency (G, I) and total number (H, J) of CD4+ (G, H) and CD8+ 
(I, J) T cells. Representative plots are pre-gated on live singlets. Numbers represent the 
frequency of events in the gate. Each dot is an individual animal. P-values were 
calculated by two-tailed, un-paired T test.  
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Figure 3. 16: T cell and macrophage proliferation and/or activation are similar in 
NOD.Postn+/+ and NOD.Postn-/- mice.  A) Representative dot plots showing Ki67 
staining on CD3+ T cells from spleen of NOD.Postn+/+ and NOD.Postn-/- mice. Plots are 
pre-gated on live CD3+ events. Frequency (B) and total number (C) of Ki67+ T cells.  
D) Representative dot plots showing Ki67 staining on CD11b+ macrophages from 
spleen of NOD.Postn+/+ and NOD.Postn-/- mice. Plots are pre-gated on live CD11b+ 
events. Frequency (E) and total number (F) of Ki67+ macrophages. G) Representative 
dot plots showing CD62L versus CD44 staining on CD4+ T cells from spleen of 
NOD.Postn+/+ and NOD.Postn-/- mice. Frequency (H, J) and total number (I, K) of 
activated (CD44+ CD62L-, H, I) and naïve (CD44- CD62L+, J, K) CD4+ T cells. 
Numbers represent the frequency of events in the gate. Each dot is an individual 
animal. P-values were calculated by two-tailed, un-paired T test.  
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Figure 3. 17: Postn does not alter survival. Bone marrow-derived macrophages were 
skewed in vitro toward an inflammatory M1 or anti-inflammatory M2 phenotype in the 
presence or absence of 100 ng/ml Postn. Bcl-2 expression was measured by qPCR. 
Each dot represents macrophages isolated from an individual animal. P-values were 
calculated by one-way ANOVA.   
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Figure 3. 18: Postn promotes macrophage chemotaxis via αM and αV integrins.  
A) Diagram of a transwell migration assay. T cells or macrophages were placed in the 
upper chamber of a transwell separated by a porous membrane; Postn was placed in 
the lower chamber of the well. Following 4 (T cells) or 18 (macrophages) hr in culture, 
the number of cells in the bottom chamber was enumerated. The concentration of Postn 
was varied from 50-1000 ng/ml.  B) CD4+ T cells were isolated from the spleen of 
neuropathic NOD.AireGW/+ mice and used in a transwell migration assay as outlined in A. 
Each dot represents an individual mouse. C) RAW cells were used in a transwell 
migration assay. Each dot represents an individual well. D) Bone marrow was isolated 
from NOD.AireGW/+ neuropathic mice and grown in the presence of GM-CSF for 5 days 
to generate bone marrow-derived macrophages, which were used in a transwell assay. 
Each dot represents an individual mouse. E) Sciatic nerve from neuropathic 
NOD.AireGW/+ mice was digested and stained for flow cytometry. A representative 
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histogram of integrin (Itg)-αV expression on CD45+ CD11b+ F4/80+ positive 
macrophages is shown. ItgαV expression is compared to a fluorescence minus one 
(FMO) control. The number represents the frequency of events within the gate. RAW 
cells (F) or bone marrow-derived macrophages (G) were used in a transwell migration 
assay with 100 ng/ml Postn in the lower chamber. IgG isotype control, α-ItgαM (CD11b), 
or α-ItgαV antibodies were included in the top chamber of the transwell. All values are 
represented as fold change compared to media alone. ****p<0.0001 Statistics were 
performed in R using the lm() function where parameters were fit to each mouse as well 
as the difference in treatment. p-values were calculated by comparing the fit of the full 
model to a model without a term for the difference in treatment and adjusted using the 
Bonferroni correction.  
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Figure 3. 19: Nerve infiltrating macrophage phenotype. RNA was isolated from the 
sciatic nerves of NOD.WT (WT) or CD3- CD11b+ macrophages enriched from sciatic 
nerve of NOD.AireGW/+ neuropathic mice. IL-12 (A), iNos (B), CD86 (C), IL-10 (D), Fizz 
(E), Mrc (F), and YM1 (G) expression relative to cyclophilin was measured by qPCR. 
Each dot represents an individual animal. P-values were calculated by two-tailed T test 
with Welch’s correction.  
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Figure 3. 20: Macrophages promote peripheral neuropathy. A-G) RNA was isolated 
from the sciatic nerves of NOD.WT (WT) or CD3- CD11b+ macrophages enriched from 
sciatic nerve of NOD.AireGW/+ neuropathic mice. CXCL9 (A), CXCL10 (B), TNFa (C), Arg 
(D), and TGFb (E) expression relative to cyclophilin was measured by qPCR. F-H) 
Sciatic nerves from NOD or NOD.AireGW/+ neuropathic mice were digested and stained 
for flow cytometry. Representative histograms showing CD80 (F), CD86 (G), or MHCII 
(H) expression on macrophages or non-macrophages from NOD or NOD.AireGW/+ 
neuropathic mice. I) Macrophages were skewed toward an M1 or M2 phenotype prior to 
inclusion in a transwell migration assay with 100 ng/ml Postn was used in the bottom 
chamber. All values are represented as fold change compared to media alone.  
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J-N) NOD.SCID recipients of NOD.AireGW/+ splenocytes were treated with vehicle or 
clodronate-containing liposomes weekly starting five weeks (arrow) post adoptive 
transfer (AT); nerve conductions were done at 10 weeks (dotted line). J) Neuropathy 
incidence curve shows fewer clodronate-treated mice develop neuropathy.  
K) Representative EMG CMAPs from untreated NOD.SCID mice, as well as NOD.SCID 
mice post adoptive transfer (AT) treated with vehicle or clodronate liposomes (note 
difference in scale of y-axis; 5 vs 20 mV); compared to vehicle, clodronate significantly 
reduced the CMAP peak amplitude (L), CMAP duration (M), and conduction velocity 
(N); each dot represents an individual mouse. *p<0.05, **p<0.005, ***p<0.0005, 
****p<0.0001 by two-tailed T test with Welch’s correction (A-E), log-rank test (J), 
ordinary one-way ANOVA with Tukey’s test for multiple comparisons (L-N).  
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Figure 3. 21: Postn does not alter macrophage polarization. Bone marrow-derived 
macrophages were skewed in vitro toward an inflammatory M1 or anti-inflammatory M2 
phenotype in the presence or absence of 100 ng/ml Postn. TNF (A), Arg (B), and iNos 
(C) expression was measured by qPCR. Each dot represents macrophages isolated 
from an individual animal. P-values were calculated by one-way ANOVA.  
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Figure 3. 22: Clodronate effectively depletes macrophages. NOD mice were treated 
with liposomes containing vehicle or clodronate. Three days post-treatment, 
splenocytes were isolated and stained for flow cytometry. CD11b+ F4/80+ 
macrophages were depleted in clodronate-treated compared to vehicle-treated mice. 
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Figure 3. 23: Macrophages are pathogenic in SAPP. NOD.Aire +/+ or NOD.AireGW/+ 
mice were treated weekly with vehicle or clodronate-containing liposomes from 7 to 14 
weeks of age. Liposome treatment was discontinued due to the development of ascites 
in clodronate-treated animals. A) Neuropathy incidence curve. B) Frequency and  
C) number of CD11b+ F4/80+ macrophages in sciatic nerve of vehicle or clodronate 
treated mice. *p<0.05 by log-rank test (A) or ordinary one-way ANOVA with Tukey’s test 
for multiple comparisons (B, C). 
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Figure 3. 24: TNFR1 deficiency protects against SAPP. A) TNFα mRNA in sciatic 
nerve of NOD.Aire+/+ (WT) and neuropathic NOD.AireGW/+ mice was measured by qPCR 
and is presented as fold change over WT. B) CD3- CD11b-, CD3+ CD11b-, and CD3-
CD11b+ cells were isolated from sciatic nerve of neuropathic NOD.AireGW/+ mice and 
TNFα mRNA was measured by qPCR. C) SAPP incidence curve of TNFR1 deficient, 
TNFR2 deficient, or TNFR1 and TNFR2 douible deficient NOD.AireGW/+ mice. RAW cells 
(D), bone marrow-derived macrophages (E), or peritoneal macrophages (F) were 
cultured in the presence or absence of Postn recombinant protein, and the 
concentration of TNFα in the supernatant was measured by ELISA. In F, supernatant 
samples were taken at 0, 3, 6, 9, 24, and 48 hours after Postn addition to the culture.  
A-B) Each dot represents an individual mouse. D-E) Each dot represents an 
independent experiment. F) Each dot represents a time point. p-values were calculated 
by two-tailed T test. 
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CAPTER 4: B CELLS ARE DISPENSIBLE FOR SPONTANEOUS AUTOIMMUNE 
PERIPHERAL NEUROPATHY DEVELOPMENT.3 
 
4.1 Introduction 
 
Autoreactive antibodies are a prominent feature of both human CIDP and murine 
SAPP (2); however, their significance in disease pathogenesis is controversial. Serum 
from human CIDP patients binds sections of healthy nerve tissue and induces 
conduction block when injected into sciatic nerve (45, 46, 48). Numerous antigenic 
targets have been proposed in CIDP including myelin proteins P0, P2, and PMP22 as 
well as various nodal proteins such as gliomedin, neurofascin, contactin-1, and caspr1. 
However, pathogenic autoantibodies can only be detected in a minority of CIDP patients 
(2). While some laboratories have observed protection against EAN (51) and SAPP (40) 
development in the absence of B cells, others failed to show any benefit to B cell 
deficiency (50). Finally, despite the presence of autoantibodies in patient serum, clinical 
trials of Rituximab in CIDP patients failed to show a benefit (3).  
Our data show that NOD.AireGW/+ µMT-/- mice lack B cells, but nevertheless 
develop peripheral neuropathy characterized by immune cell infiltration of peripheral 
nerve, demyelination and impaired nerve function. Thus, B cells are dispensable for 
SAPP development. 
                                                          
3 Figure 4.3 of this chapter originally appeared in The Journal of Immunology 
Smith, C.J., Allard, D.E., Wang, Y., Howard, J.F., Jr., Montgomery, S.A., and Su, M.A. 2018. IL-10 
Paradoxically Promotes Autoimmune Neuropathy through S1PR1-Dependent CD4(+) T Cell Migration. J 
Immunol 200:1580-1592. 
Student contribution: I performed experiments and analyzed the data contained in this chapter. I wrote all 
of the text and made the figures. 
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4.2 Results 
 
4.2.1 Marginal zone B cells are increased in SAPP 
 
Because NOD.AireGW/+ have increased titers of autoreactive antibodies and MZ B 
cells are known to produce many autoreactive antibodies (164), we hypothesized that 
NOD.AireGW/+ neuropathic mice may have an increased frequency of MZ B cells. 
Indeed, neuropathic NOD.AireGW/+ neuropathic animals had significantly increased 
CD19+ CD138- CD21+ CD23- MZ B cells compared to NOD.Aire+/+ controls (Figure 
4.1A, C). Additionally, MZ B cells in NOD.AireGW/+ neuropathic animals had significantly 
higher CD21 mean fluorescence intensity (MFI) compared to NOD.Aire+/+ controls 
(Figure 4.1B). While MZ B cells were increased, CD19+ CD138- CD21- CD23+ FO B 
cells (Figure 4.1A, D) and CD19+ CD138- CD21- CD23- Tr B cells (Figure 4.1A, E) had 
a corresponding decrease in frequency and number.  
4.2.2 B cells are dispensible for SAPP pathogenesis. 
 
Reports of residual B cells and antibodies being produced in µMT-/- mice have 
been made (165-167). It is possible that in the absence of µ heavy chain, B cells can 
use IgA for development (167). In order to determine whether residual B cells or 
antibodies were present in our mice we stained splenocytes for CD19 and IgG/M 
antibodies using flow cytometry. Approximately 40% of splenocytes isolated from 
NOD.AireGW/+ µMT+/- mice were CD19+ IgG/M+ double positive; however, no B cells 
were observed in the spleens from NOD.AireGW/+ µMT-/- mice (Figure 4.2A, B). 
Additionally, serum of NOD.AireGW/+ µMT-/- mice lacked antibodies as measured by 
ELISA (Figure 4.2C). In combination, these data confirm that NOD.AireGW/+ µMT-/- mice 
lack B cells and antibodies.  
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NOD.AireGW/+ µMT+/-, and NOD.AireGW/+ µMT-/- mice were monitored for the 
development of neuropathy. Surprisingly, no difference was observed in the disease 
incidence of NOD.AireGW/+ µMT-/- mice compared to NOD.AireGW/+ µMT+/- mice (Figure 
4.3A). Electrophysiology revealed similar CMAP peak amplitude, CMAP duration, and 
conduction velocity in B cell deficient NOD.AireGW/+ µMT-/- and B cell sufficient 
NOD.AireGW/+ µMT+/- mice (Figure 4.3B, C) indicating that disease severity was similar in 
both groups of mice. Furthermore, similar levels of sciatic nerve infiltration were 
observed in B cell sufficient and deficient NOD.AireGW/+ mice by hematoxylin and eosin 
staining (Figure 4.4).  
4.2.3 Treg cells are reduced in spleen but not the nerve of B cell deficient SAPP mice. 
 
The simultaneous depletion of a pathogenic and a regulatory population could 
obscure our ability to observe the pathogenic effects of B cells. Indeed, mice harboring 
the µMT mutation have reduced FoxP3-expressing T regulatory cell (FoxP3+ Treg) 
frequency (168). Since reduced FoxP3+ Treg frequency predisposes to the 
development of autoimmunity including SAPP (28), a reduction in FoxP3+ Treg in µMT 
deficient mice could theoretically mask the protective effects of B cell deficiency. In 
order to test the hypothesis that a reduction in FoxP3+ Treg could be masking the effect 
of B cell deficiency in our model, we stained the spleen and sciatic nerves of 
NOD.Aire+/+, NOD.AireGW/+ µMT+/-, and NOD.AireGW/+ µMT-/- mice for FoxP3 and CD25. 
CD4+ FoxP3+ CD25+ cell frequency and total number were reduced in NOD.AireGW/+ 
µMT-/- spleen compared to NOD.AireGW/+ µMT+/-; however, FoxP3+ Treg frequency and 
number was similar in the sciatic nerves of NOD.AireGW/+ µMT+/-, and NOD.AireGW/+ µMT-
/- mice (Figure 4.5).  
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4.2.4 Regulatory B cell populations are unaltered in SAPP mice. 
 
Although we observed no change in the FoxP3+ Treg population in the nerve of 
SAPP mice, other regulatory populations such as regulatory B cells (Breg) exist and the 
µMT mutation prevents the development of both Breg and B effector subsets. However, 
whether Breg cells are present in neuropathic NOD.AireGW/+ mice is unknown. We 
measured the frequency and number of IL-10-producing Breg cells (B10) in the spleen 
and peritoneal cavity of NOD.Aire+/+ and NOD.AireGW/+ mice by flow cytometry (Figure 
4.6). Neither the frequency nor the number of B10 cells was altered in NOD.AireGW/+ 
mice compared to controls. 
B1 cells are another B cell subset with reported regulatory function (169). We 
used flow cytometry to characterize the B1 cells in the peritoneum of NOD.Aire+/+ and 
NOD.AireGW/+ mice. The frequency and number of both CD19+ CD11b+ CD5+ B1a and 
CD19+ CD11b+ CD5- B1b cells was unchanged in NOD.AireGW/+ mice compared to 
NOD.Aire+/+ controls (Figure 4.7).  
4.2.5 T cell activation is unchanged in B cell deficient SAPP mice. 
 
 B cells can act as antigen presenting cells to T cells (170); therefore, we 
wondered whether T cell activation was changed in B cell deficient mice. To test this we 
measured expression of CD44 and CD62L on T cells by flow cytometry. The frequency 
and number of CD4+ CD44- CD62L+ naïve T cells and CD4+ CD44+ CD62L- activated 
T cells was unchanged in NOD.AireGW/+ µMT-/- compared to NOD.AireGW/+ µMT+/- mice 
(Figure 4.8).  
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4.3 Discussion 
 
 In this study we showed that MZ B cells are increased in neuropathic 
NOD.AireGW/+ mice compared to NOD.Aire+/+ non-neuropathic controls. Despite an 
increased frequency this autoimmune-prone B cell population, we observed no 
difference in SAPP disease course or severity in B cell deficient animals compared to B 
cell sufficient controls. Simultaneous changes in regulatory T or B cell subsets or 
changes in T cell activation in the setting of B cell deficiency could mask our ability to 
observe the beneficial effect of depleting pathogenic B cells. We observed a decrease 
in FoxP3+ Tregs in the spleen but not the nerve of B cell deficient animals; however, we 
did not observe changes in Bregs, B1 B cells, or T cell activation. In light of these 
results it is unlikely that changes in FoxP3+ Tregs, Bregs, or T cell activation status are 
masking the effects of depleting pathogenic B cells. Therefore, we conclude that B cells 
are not pathogenic in the NOD.AireGW/+ model of SAPP.    
 Our results mirror those of Zhu et al. who observed no improvement in EAN in B 
cell deficient mice immunized with P0180-199 peptide (50). However, disease severity in 
mice with EAN induced by immunization with P0106-125 peptide is reduced in B cell 
deficient mice (51). Additionally, CD19-specific antibody therapy reduced disease 
severity in a B7-2 deficient model of SAPP (40). The conflicting results observed by our 
group and others may reflect the different methods used to induce disease and are 
consistent with the heterogeneity observed in autoantibody presence and specificity in 
human CIDP and GBS. Only 5% of CIDP patients have detectable autoantibodies in 
serum suggesting that B cell-independent mechanisms predominate in a majority of 
CIDP patients (2). Similarly, the role of autoantibodies is more prominent in axonal 
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forms of GBS such as acute motor axonal neuropathy (AMAN) and acute motor and 
sensory axonal neuropathy (AMSAN) than demyelinating forms such as acute 
inflammatory demyelinating polyneuropathy (AIDP) (6).  
4.4 Methods 
 
4.4.1 Animals 
 
 Strains and housing. Mice were housed in a specific pathogen-free facility at the 
University of North Carolina at Chapel Hill (UNC-CH). NOD.AireGW/+ mice were 
generated as previously described (25). NOD.µMT-/- (JAX stock #004639) mice were 
purchased from the Jackson Laboratory. 
 Evaluation of SAPP: Neuropathy was assessed weekly using two methods: 
rotarod performance and clinical score. The number of seconds a mouse could stay on 
a rotating rod was measured for a maximum of 300 seconds. Mice were considered to 
be neuropathic when their rotarod time dropped below 100 seconds. Clinical score was 
determined as follows: 0-no signs of neuropathy present, 1-mild hind limb weakness, 2-
pronounced bilateral hind limb weakness, 3-reduced or absent ability to grip cage 
grating, 4-moribund. For neuropathy incidence curve, mice were considered 
neuropathic when they reached a score of 2 in order to limit the effect of false positives. 
SAPP was confirmed by electromyography, which was performed as previously 
described (27, 110). 
4.4.2 Flow Cytometry 
 
 Nerve digestion: Nerves were chopped into segments with a razor blade and 
digested in PBS containing 1 mg/ml collagenase and 1% FBS at 37°C for 30 min with 
periodic agitation. Part-way through the digestion, the sample was triturated with a 20g 
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needle to aid in tissue disruption. Dissociated nerves were filtered through 40 µm mesh 
and washed prior to use in experiments.   
 Antibodies: B220 (clone RA3-6B2), CD23 (clone B3B4), CD5 (clone 53-7.3), IL-
10 (clone JES5-16ES), CD3 (Clone 145-2C11), CD4 (Clone RM4-5), and CD8 (clone 
53-6.7), FoxP3 (clone FJK-16s), CD25 (clone PC61.5), CD44 (clone IM7), CD62L 
(clone MEL-14) antibodies were purchased from eBioscience. CD19 (clone 6D5), 
CD138 (clone 281-2), CD1d (clone 1B1), CD11b (Clone M1/70) was purchased from 
BioLegend. CD21 (clone 7E9) was purchased from Life Technologies. Live/dead fixable 
yellow dye (Life Technologies) was used to exclude dead cells.  
 Staining. Single cell suspensions were washed twice with FACS buffer. Fc 
receptors were blocked by incubating cells with supernatant from a 2.4G2 hybridoma for 
10 min. Cells were stained for 30 min on ice and washed prior to analysis. 
 Intracellular cytokine staining. Splenocytes or peritoneal cells were stimulated 
with PMA, ionomycin, and LPS for 5 hours in the presence of Golgistop prior to staining 
for B10 regulatory cells as previously described. Following extracellular staining, cells 
were fixed and permeabilized using the BD Cytofix/Cytoperm Fixation/Permeabilization 
Solution Kit according to manufacturer’s instructions and stained for IL-10.   
 FoxP3 staining. Following surface staining, cells were fixed and permeabilized 
using eBioscience FoxP3/Transcription Factor Staining Buffer Set according to 
manufacturer’s instructions. 
 Analysis: Samples were run on Beckman Coulter CyAn ADP flow cytometer and 
analyzed using FlowJo software.  
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Figure 4. 1: The frequency of marginal zone B cells is increased in NOD.AireGW/+ 
mice. A) Representative dot plots of CD21 versus CD23 staining on CD19+ CD138- 
splenocytes isolated from NOD.Aire+/+ (WT) and neuropathic NOD.AireGW/+ (GW) mice. 
Numbers represent the frequency of cells in the gate. B) Representative histogram (left) 
and cumulative MFI (right) of CD21 fluorescence on CD21+ CD23- marginal zone (MZ) 
B cells. Frequency (left) and number (right) of (C) CD21+ CD23- MZ, CD21- CD23+ 
follicular (FO), and CD21- CD23- transitional (Tr) B cells. Each dot represents and 
individual animal. Horizontal lines represent the mean. P values were determined by 
two-tailed T test.  
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Figure 4. 2: NOD.AireGW/+µMT-/-
 
mice lack IgG antibodies and mature B cells.  
(A) Representative flow cytometric plots of CD4-, CD8- splenocytes. CD19 versus IgG, 
A, M. Numbers represent the average frequency of B cells in the spleen. (B) Total serum 
IgG concentration was measured by ELISA. (C) Percent and (D) total number of B cells 
in the spleen. Dots represent individual mice. Horizontal lines are averages. ****denotes 
p<0.0001 
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Figure 4. 3: B cell deficiency does not protect from SAPP. WT µMT–/–, AireGW/+ 
µMT+/–, and AireGW/+ µMT–/– mice were monitored for SAPP. (A) SAPP incidence curve. 
p-value was calculated using Mantel-Cox log-rank test of AireGW/+ µMT+/– versus 
AireGW/+ µMT–/– mice; ns indicates no significant difference observed.  
(B) Representative proximal and distal compound muscle action potentials from sciatic 
nerves of 22-wk-old mice. (C) Cumulative peak amplitude, conduction velocity, and 
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duration of compound muscle action potentials of 22-wk-old mice. p-value was 
calculated using one-way ANOVA with Tukey’s correction for multiple comparisons; ns 
indicates no significant difference observed. Each symbol represents an individual 
mouse. Copyright 2018. The American Association of Immunologists, Inc. (171) 
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Figure 4. 4: Nerves of NOD.AireGW/+ µMT-/- mice are infiltrated. Longitudinal sections 
of sciatic nerve from NOD.Aire+/+, NOD.AireGW/+ µMT+/-, and NOD.AireGW/+ µMT-/- mice 
were stained with hematoxylin and eosin. Note that similar infiltration of sciatic nerve is 
observed in the presence or absence of B cells. 
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Figure 4. 5: FoxP3+ Tregs are reduced in spleen but not nerve of NOD.AireGW/+ 
µMT-/- mice. Spleen and sciatic nerve from NOD.Aire+/+ (WT), NOD.AireGW/+ µMT+/- 
(GW), and NOD.AireGW/+ µMT-/- mice was stained for FoxP3+ Tregs. Representative dot 
plots of CD25 versus FoxP3 staining on CD4+ T cells is shown in A. Numbers represent 
the frequency of cells in the gate. B) The cumulative   frequency of CD25+ FoxP3+ Treg 
in spleen (left) and sciatic nerve (right). Each dot represents an individual animal. 
Horizontal lines are averages. p-values were calculated using a two-tailed T test. ns = 
not significant.   
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Figure 4. 6: B10 regulatory cells are similar in NOD.Aire+/+ and NOD.AireGW/+ mice. 
A) Representative dot plots of CD19 versus IL-10 staining on splenocytes and 
peritoneal cells in NOD.Aire+/+ (WT) and neuropathic NOD.AireGW/+ (GW) mice. 
Numbers represent the frequency of cells in the gate. B) Frequency (left) and number 
(right) of CD19+ IL-10+ B cells (B10) in spleen (top) and peritoneum (bottom). Each dot 
represents an individual animal. Horizontal lines are averages. p-values were calculated 
using a two-tailed T test. No significant difference was observed. 
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Figure 4. 7: B1 cell frequency is unaltered in NOD.AireGW/+ neuropathic mice.  
B cells were harvested from the peritoneal cavity of NOD.Aire+/+ (WT) and NOD.AireGW/+ 
(GW) mice and stained for flow cytometry. A) Representative dot plots of CD19+ B cells 
stained for CD11b and CD5. Numbers represent the frequency of cells in the gate.  
B) Frequency (left) and total number (right) of CD11b+ CD5+ B1a cells. C) Frequency 
(left) and total number (right) of CD11b+ CD5- B1b cells. Each dot represents an 
individual animal. Horizontal lines are averages. p-values were determined by two-tailed 
T-test. No significant difference was observed. 
 
111 
 
 
Figure 4. 8: T cell activation is unaltered in B cell deficient mice. A) Representative 
dot plots of CD4+ cells isolated from spleen of NOD.Aire+/+, NOD.AireGW/+ µMT+/- , and 
NOD.AireGW/+ µMT-/- mice. Numbers represent the frequency of cells in the gate. 
Frquency (left) and number (right) of CD44+ CD62L- (B) and CD44- CD62L+ (C) cells. 
Each dot represents an individual animal. Horizontal lines are averages. p-values were 
calculated using a two-tailed T test. No significant difference was observed. 
  
112 
 
 
 
 
 
 
CHAPTER 5: DISCUSSION 
 
5.1 CD49b/C1q: potential mediators of inflammation in SAPP 
 
 In chapter 2, we showed that CD49b was expressed by Schwann cells and was 
upregulated during SAPP. Furthermore, we demonstrated that CD49b associated with 
complement protein C1q. However, the functional significance of CD49b upregulation 
during SAPP and its association with C1q is unclear. Experiments disrupting CD49b 
expression are critical next steps in understanding the role of CD49b in SAPP. This 
could be achieved either with CD49b-depleting antibodies or by genetic knock out of 
CD49b. CD49b inhibitors are currently being developed for the treatment of cancer 
(172), and mice with CD49b deficiency are generally healthy and fertile (173, 174) 
therefore, both pharmacological and genetic CD49b depletion experiments are feasible 
options. Since integrins have considerable functional redundancy, interpretation of 
these studies may be complicated. If CD49b depletion fails to protect mice from SAPP, 
simultaneous depletion of two or more integrins may be necessary to observe a 
phenotype.  
Another outstanding question is whether the association between CD49b and 
C1q observed in SAPP promotes pathogenesis and if so, by what mechanism. To test 
this, we could measure C1q association with Schwann cells in the setting of CD49b 
deficiency in vivo. CD49b/C1q interaction regulates IL-6 expression (54, 175), and 
Schwann cells express IL-6 during WD (16). Therefore, CD49b and C1q may be 
involved in cytokine induction in Schwann cells (Figure 5.1). This could be tested by 
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measuring the expression of IL-6 and other Schwann cell-associated cytokines in 
response to C1q exposure in the presence or absence of CD49b. Additionally, CD49b 
and C1q are required for entry of Bacillus antracis into host cells (176) implying a role 
for CD49b/C1q in endocytosis. Whether CD49b/C1q play a role in myelin phagocytosis 
during SAPP could be tested in vitro by feeding cultured Schwann cells fluorescent 
myelin and measuring the amount of fluorescence in CD49b-depleted or C1q-depleted 
conditions. 
Inhibitors of CD49b (172) are in development for the treatment of cancer. 
Additionally, C1q depletion is an effective treatment for EAN (97). Our data that CD49b 
is upregulated on Schwann cells during SAPP and associated with C1q motivate further 
investigations on the role of CD49b and C1q in CIDP and their potential as therapeutic 
targets.   
5.2 Postn-mediated immune cell recruitment 
 
 In chapter 3, we showed that Postn directly promotes chemotaxis of 
macrophages (Figure 5.2) but not T cells in vitro; however, both T cell and macrophage 
numbers are reduced in the sciatic nerve of Postn deficient mice with neuropathy. The 
mechanism by which Postn regulates T cells in vivo is thus unclear. One possibility is 
that Postn regulates T cell infiltration of the sciatic nerve indirectly through macrophage 
recruitment since macrophages are known to secrete T cell chemokines (177). Another 
possibility is that Postn regulates the expression of T cell chemokines since Postn has 
been shown to regulate various chemokines including CCL17 (81) and RANTES (82, 
93). This could be tested by measuring chemokine expression in sciatic nerve of Postn 
sufficient and deficient mice.    
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We show that Postn expression increases during inflammatory neuropathy in the 
PNS. Similarly, Postn is upregulated in the CNS following hypoxic (178, 179) or 
mechanical injury (90) and in glioblastoma (91). Our results that Postn acts as a 
chemotactic factor for macrophages in SAPP are consistent with reports of Postn-
mediated macrophage chemotaxis following spinal cord injury (90) and in glioblastoma 
(91) and suggest that Postn may be an important chemoattractant for macrophages in 
neuropathology more generally. Macrophages are recruited to the nervous system 
during autoimmunity, following injury (150, 180), and in some hereditary neuropathies 
(152). Whether Postn plays a role in macrophage infiltration in hereditary neuropathies 
such as CMT, or in autoimmune demyelination of the CNS is yet to be determined.  
 Inhibitors of Postn (158, 159) and its receptor ItgαV (160, 161) are in various 
stages of development for the treatment of cancer. Our finding that Postn promotes 
inflammatory neuropathy through ItgαV-dependent macrophage recruitment suggests 
that inhibition of Postn or ItgαV may be effective treatment options for inflammatory 
neuropathies. Our results provide a basis for the development of these molecules as 
novel therapeutics for inflammatory neuropathies.  
5.3 TNFα promotes SAPP 
 
 In chapter 3, we found that endoneurial macrophages produce high levels of 
TNFα. Additionally, we found that deletion of TNFR1 but not TNFR2 prevented SAPP  
development in NOD.AireGW/+ mice. These results indicate a role for TNFα and TNFR1 
in SAPP pathogenesis; however, the mechanisms by which TNFα promotes SAPP are 
unknown. Several potential mechanisms are suggested by the literature. First, TNFR1 
plays a critical role in MHCII expression by and antigen presenting function of Schwann 
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cells during EAN (181). Second, TNFα induces macrophage recruitment and nerve 
inflammation when injected directly into nerve (182). Third, TNFα is crucial for FoxP3+ 
Treg development (183). Adoptive transfer studies in mice with TNFR1 deficiency in 
donors, recipients, or both could help determine whether TNFα and TNFR1 are acting 
locally in the nerve or in the immune cell compartment and will direct future research.  
Our results indicating a pathogenic role of TNFα are exciting because TNFα 
depleting antibodies are currently in use as an effective therapy for autoimmune arthritis 
(184). On the other hand, TNFα antibodies are not effective in multiple sclerosis (MS), 
an autoimmune demyelinating disorder of the CNS, and even made some patients 
worse (185). In a toxin-induced model of MS, TNFα is critical for remyelination of the 
CNS. TNFR2 is expressed by oligodendrocyte precursor cells (OPCs) and signaling 
through TNFR2 is important for OPC proliferation (186). Whether TNFR2 plays a similar 
role in myelin repair following peripheral nerve autoimmune attack is unclear. Therefore, 
care must be taken when translating these results into the clinic for treatment of CIDP 
and GBS.  
5.4 Phenotypic variation in CIDP and GBS: the role of B cells 
 
    Numerous phenotypic variants exist among CIDP and GBS patients. Typical 
CIDP involves proximal and distal, symmetric dysfunction of both sensory and motor 
neurons; however, CIDP has several phenotypic variants which are classified based on 
the relative involvement of sensory and motorneurons and the pattern of peripheral 
nerve and nerve root involvement (2). Similarly, several variants of GBS have been 
identified including both demyelinating and axonal forms (112).  
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In GBS, autoantibodies are present in 80% of axonal GBS cases, but only 10% 
of demyelinating GBS cases (187) suggesting that antibodies play distinct roles in 
axonal and demyelinating forms of GBS. Similarly, pathogenic autoreactive antibodies 
have been found in only a minority of patients with CIDP (2). Additionally, different 
autoantibody specificities induce axonal compared to demyelinating pathology. For 
example, while both contactin and gliomedin-specific autoantibodies disrupt the node of 
Ranvier and block nerve conduction, only gliomedin-specific autoantibodies were able 
to induce demyelination (44, 49).  
In chapter 4, we observed no difference in SAPP onset or disease severity in B 
cell deficient compared to B cell sufficient animals. Our results are similar to those of 
Zhu et al. who found that EAN induced by P0180-199 did not require B cells (50). 
However, other groups have shown that B cells contribute to peripheral nerve 
autoimmunity via production of pathogenic autoantibodies and antigen presentation (40, 
51, 188). The conflicting results of B cell depletion in murine models of inflammatory 
neuropathy may reflect the heterogeneity with respect to disease symptoms and 
autoantibody presence observed in CIDP and GBS. Further characterization of which 
autoantibody specificities associate with particular CIDP and GBS variants will help 
clarify the role of B cells and antibody in peripheral neuropathies. 
5.5 Conclusion  
 
Research into the pathogenesis of autoimmune peripheral neuropathies such as 
CIDP and GBS has largely focused on the role of immune cells as pathogenic 
mediators of disease; however, we show here that Schwann cells and the ECM protein 
Postn also participate in the immune response during autoimmune peripheral 
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neuropathy. Whether Schwann cells play other roles in PNS autoimmunity such as 
antigen presentation and cytokine secretion is unclear. Furthermore, whether other 
extracellular matrix proteins may contribute to autoimmunity in the PNS is unknown and 
would be an interesting area of future study. These findings highlight the importance of 
Schwann cells and ECM proteins in CIDP and GBS pathogenesis and suggest that 
further research may uncover valuable new treatment options for PNS autoimmunity.  
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Figure 5. 1: Potential functions of CD49b/C1q interaction in SAPP. Following nerve 
injury, Schwann cells phagocytose myelin debris. Since C1q can bind myelin directly, 
and CD49b/C1q interactions have been implicated in endocytosis of pathogens, we 
hypothesize that CD49b and C1q may be important regulators of myelin phagocytosis 
by Schwann cells during SAPP (1). Alternatively, Schwann cells are known to express 
inflammatory cytokines including IL-6 during SAPP. CD49b/C1q interactions have been 
reported to regulate the expression of IL-6; therefore, we hypothesize that CD49 and 
C1q may regulate cytokine expression in Schwann cells as well (2). 
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Figure 5. 2: Schwann cell-derived Postn promotes SAPP through macrophage 
recruitment. During SAPP, T cells traffic from the blood into the endoneurium (1). In 
response to TGFb, Schwann cells upregulate Postn, secrete it into the endoneurium, 
and establish a concentration gradient (2). Upon binding of Postn to ItgaM or ItgaV, 
macrophages (M) migrate from the blood into the endoneurium. Macrophages then 
secrete CXCL9 and CXCL10 (3) to recruit additional T cells to the endoneurium, thus 
amplifying a positive feedback loop.  
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